Title:

Bezisterim-associated anti-inflammatory epigenetic modulation of age acceleration and Alzheimer's disease genes

Short title:

Reduced epigenetic age with bezisterim

Authors:

Christopher Reading[1], Jiayan Yan[1], Clarence Ahlem[1], Penelope Markham[1], Stephen O'Quinn[1], Joseph M. Palumbo[1], Varun B. Dwaraka[2*]

[1]BioVie Inc., Carson City, NV, USA; [2]TruDiagnostic, Inc., Lexington, KY, USA

*Corresponding author

Varun B. Dwaraka

TruDiagnostic, Inc.

Lexington, KY, USA

Email: varun.dwaraka@trudiagnostic.com

ORCID: https://orcid.org/0000-0001-9033-3092

Abstract

Treatments with the ability to slow or reduce biological age have therapeutic potential in diseases of aging, including late-onset Alzheimer's disease (AD). We previously reported that bezisterim, a novel anti-inflammatory insulin sensitizer, modulated epigenetic age acceleration (EAA) in a randomized, placebo-controlled, 30-week AD trial. Here, we expand on those findings through integrative mechanistic analyses and by linking bezisterim-induced EAA changes with clinical outcomes. Thirty weeks of bezisterim treatment in patients with mild-to-moderate AD significantly reduced EAA across 13 independent biological clocks versus placebo. The reduced EAA was predominantly associated with biomarkers of inflammation and cognition, including transcriptional regulators that orchestrate broader gene networks. Genome-wide methylation profiling revealed 2,154 genes with significant differential promoter methylation (DPM) between bezisterim and placebo groups. Among those DPM genes, increased promoter methylation was observed in 432 genes associated with microglial neuroinflammation, pro-inflammatory kinase activity, cognitive decline, lipid metabolism, and transcriptional regulation, whereas decreased methylation was observed in 15 genes that might increase autophagy and anti-inflammatory phosphatases, and might decrease macrophage polarization. Finally, separate correlational analyses among the bezisterim and placebo groups suggest that the observed changes in potentially beneficial DPM genes might contribute to the previously reported clinical effects of bezisterim in AD. Notably, the majority of correlations in bezisterim-treated patients were associated with neurologic and metabolic improvements; 11 of these DPMs were correlated with two to five clinical measures each. Bezisterim appears to exert pleiotropic effects through coordinated modulation of aging-related epigenetic programs, potentially counteracting neurodegenerative processes at the intersection of inflammation, metabolism, and transcriptional control.

Keywords

1. Introduction

The pathogenesis and progression of Alzheimer's disease (AD) have historically been attributed to the accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles, which are believed to trigger innate immune responses from damage-associated molecular patterns (DAMPs), accelerate aging, and alter transcriptional profiles (Breijyeh & Karaman, 2020; Deczkowska et al., 2018; Srinivasan et al., 2020; Y. Wei & Li, 2022; J. Zhang et al., 2024). However, more recently, neuroinflammation has emerged as a third core pathology of AD, whereby sustained inflammatory signaling contributes to neuronal dysfunction and atrophy in cognitive disorders (Heneka et al., 2015; Jin, Chan, Wu, & Lee, 2022; Kamila et al., 2025; Y. Ma et al., 2023).

The exact mechanisms by which the inflammatory signaling pathways that contribute to normal aging processes become dysregulated in AD and other neurocognitive disorders remain to be elucidated, but likely involve the induction of persistent immune activity via DAMPs (M. Ma, Jiang, & Zhou, 2024). In one such inflammatory environment, the "Warburg effect" triggers normal-state ("M0") macrophages and microglia into a pro-inflammatory state ("M1") that favors glycolysis over oxidative phosphorylation (Liberti & Locasale, 2016). The resulting metabolic inflammation impairs insulin signaling to create a cycle of dysregulated glycolysis, lipid synthesis, pro-inflammatory kinase cascades, chromatin remodeling, and altered transcription factor (TF) activity. Notably, altered insulin signaling contributes to chronic inflammation in other diseases of aging, including diabetes, obesity, and cardiovascular disease. For example, peripheral impaired glucose tolerance and type 2 diabetes (T2D) can trigger insulin resistance (IR) in the brain (Chow et al., 2019). IR can then increase Aβ, phosphorylated Tau (pTau), oxidative stress, advanced glycation end products, and apoptosis (Rorbach-Dolata & Piwowar, 2019), suggesting a shared immune-mediated mechanism of neurodegeneration across some diseases of aging.

Epigenetic modification of these inflammatory signaling pathways has recently been identified as a key regulator of disease progression in AD (Gao et al., 2022; Kinney et al., 2018; Y. Ma et al., 2023). Thus, novel therapies that can target epigenetic markers and decrease age-related inflammation may alter AD progression. Bezisterim, which has been shown to have a favorable safety profile, is an oral, blood-brain barrier–permeable, anti-inflammatory, insulin-sensitizing analog of the neurosteroid androst-5-ene-3β,7β,17β-triol (beta-AET) (Ahlem et al.,

2011; C. Reading et al., 2025; C. L. Reading, Flores-Riveros, Stickney, & Frincke, 2013; C. L. Reading, Stickney, et al., 2013). We previously reported an exploration of potentially beneficial differences in neurologic and metabolic measures, as well as DNA methylation (DNAm) measures, between bezisterim and placebo patients with mild-to-moderate AD (C. Reading et al., 2025). Here, we present findings from an analysis of genes that showed a significant difference in average differential promoter methylation (DPM) in the aforementioned study – i.e., those associated with changes in expression – and genes discovered in previous publications to be related to metabolic inflammation. Besides DNAm, we also report on epigenetic changes influencing chromatin reorganization (i.e., histone modifications) (Y. Lin et al., 2022) and alterations in TF activities as they relate to inflammatory gene expression.

2. Materials and Methods

2.1. DNAm assessment

Whole blood specimens from the completion visit were collected in EDTA tubes, frozen and shipped to the Epigenetic Clock Development Foundation for processing on Illumina Infinium MethylationEPIC v2.0 (EPICv2) BeadChips as was previously described (C. Reading et al., 2025). Briefly, blinded samples were randomized to chips and processed in two batches using the standard Illumina Infinium workflow; 37 samples were assayed and 33 passed Illumina quality control for downstream DNAm analyses. IDAT files were generated and sent to TruDiagnostic for further DNAm data processing.

2.2. DNAm data preprocessing (minfi-based)

R raw IDATs were read with minfi (read.metharray) and assigned the EPIC v2.0 manifest (IlluminaHumanMethylationEPICv2; 20a1.hg38) (Aryee et al., 2014). A per-run quality control report was generated. Probe-level detection P values were computed from methylated + unmethylated signals (detectionP, type = "m+u"). Samples with mean detection $P > 0.05$ were flagged *a priori* for exclusion; in this dataset no samples were removed, and 5'-cytosine-phosphate-guanine-3' (CpG)-level filtering at the same threshold was evaluated but not applied. Background correction and dye-bias normalization used Noob (preprocessNoob, dyeMethod = "single"), after which beta values were exported (Fortin, Triche, & Hansen, 2017). Probe intensities were collapsed to EPIC v2.0 pfx-level targets to harmonize duplicated probe families

to allow for compatibility for clock quantification. For legacy models requiring HM450/EPIC v1.0 CpGs, missing sites were augmented using array- and tissue-specific medians from sesame's imputation defaults (EPIC.imputationDefault,Blood), ensuring coverage of required loci across methods. The resulting normalized beta matrix and the corresponding RGChannelSet were saved as .RDS files for reproducibility.

2.3. Deriving estimates of epigenetic clocks and methylation-based metrics

Epigenetic ages and related methylation metrics were computed from the cleaned beta matrix using validated implementations or author-provided code. Canonical clocks (Horvath multi-tissue [Horvath, 2013], Horvath skin-and-blood [Horvath et al., 2018], Hannum [Hannum et al., 2013], PhenoAge, GrimAge [components and composite; A. T. Lu et al., 2019] and DNA methylation telomere length [DNAmTL; A. T. Lu et al., 2019]) were estimated; where applicable, principal-component (PC) implementations were used to enhance reliability (Higgins-Chen et al., 2022). System-specific aging (SystemsAge) was quantified by projecting blood DNAm PCs onto organ-system axes (blood, brain, inflammation, heart, hormone, immune, kidney, liver, metabolic, lung, musculoskeletal), scaling predictions to years, and converting to age-adjusted residuals using reference-cohort parameters before re-centering to absolute system ages (Sehgal et al., 2025). Additional causal/stochastic and other clocks (AdaptAge, CausAge, DamAge [Ying et al., 2024]; stochastic Horvath/Hannum/PhenoAge/Zhang [Tong et al., 2024]; IntrinClock with adult-age back-transformation [Tomusiak et al., 2024]; and RetroClock v1/v2 [Ndhlovu et al., 2024]) were generated from published coefficient tables or locked models.

For downstream analyses, epigenetic metrics (e.g., clocks, telomere proxy, immune deconvolution, Epigenetic Biomarker Proxies, EpiScores) were age- and covariate-adjusted using linear models that included chronological age, sex, and cell-type fractions; SystemsAge followed its published calibration procedure. All scripts were written in R (key packages: minfi, sesame, EpiDISH, ENmix, glmnet, data.table, tidyverse), and model resources (PC-clock rotations, SystemsAge coefficients,) were loaded from locked RData/.CSV files. Final outputs included per-participant tables of clock values, cell-type estimates and ratios, SystemsAge domains, and ancillary predictors for statistical testing.

2.4. Analysis of changes in promoter methylation between bezisterim and placebo

Of the DNAm samples processed, 33 met quality control criteria and were retained for downstream analysis. Promoter region methylation levels were extracted, and the mean β value across CpG sites in promoter regions was calculated for each CpG. Average differences in promoter methylation between the bezisterim group (N=17) and placebo group (N=16) were computed for each gene based on UCSC_RefGene_Name annotations. Statistical significance of these differences was evaluated using parametric testing, and *P* values were corrected for multiple testing by the Benjamini-Hochberg false discovery rate (FDR) procedure, with a significance threshold of FDR < 0.05. Between-group differences in bezisterim and placebo for epigenetic age acceleration (EAA) were estimated by calculating the residual of the clock to age, and adjusting for sex, the first three potential components, and genotype. Statistical tests used were unpaired t-test with Welch correction.

Genes were further filtered to retain only those with an absolute mean methylation difference ≥ 5% (rounded to the nearest integer). These genes were designated as DPM genes and underwent subsequent downstream analyses.

2.5. Genes associated with EAA in biological clocks

The genes associated with CpGs were identified for clocks with significant differences in EAA, and these genes were cross-referenced for DPM matches and termed "DPM clock genes."

2.6. Artificial intelligence (AI) disclosure

Each gene in Table S2a (Supplementalary File 1) was searched in Chrome using AI mode separately for the following traits: "Alzheimer," "Nominated target," "Microglial neuroinflammation," "Inflammation," "Cognition," "Diabetes," "Obesity," "M1 polarization," "Glycolysis," "Kinase cascades," "Phosphoprotein," "Lipids," "Chromatin remodeling," and "Transcription factor." Potentially beneficial changes in genes were identified and curated from the published data, with specific links provided in Supplementalary File 3.

3. Results
3.1. Epigenetic clocks

We assessed the effects of bezisterim on 13 independent EAA clocks that address various processes, including biological aging, mortality, immune-cell-composition-independent aging,

disease-injury-related DNAm, random changes in DNAm related to aging, epigenetic changes in long interspersed nuclear element-1 (LINE-1), and epigenetic aging for the Heart, Lung, and SystemsAge overall organ systems (Figure 1). The rate of age acceleration across all 13 clocks was statistically significantly reduced in samples from bezisterim-treated AD participants (n=17) versus samples from placebo-treated AD participants (n=16) (Figure 1), suggesting that bezisterim may modulate the progression of aging-related epigenetic changes in AD.

3.2. Gene investigations

Supplementary File 1, Table S1, reports on genes whose differential expression might contribute to previously reported benefits of bezisterim on age deceleration, clinical assessments, and metabolic and inflammatory biomarkers. Various activity parameters investigated indicate significant bezisterim differences versus placebo.

3.3. Differences in DNA promoter methylation

Of 2,154 bezisterim-associated potentially beneficial DPM (PBDPM) genes, 2,136 had increased DPM and only 18 had decreased DPM. Table 1 lists details for the displayed DPM genes in Figure 2, including the number of methylated CpGs in the promoter, percentage of DPM, FDR-adjusted P values, descriptions of their activities, and references. Volcano plots (Figure 2) for the differences in DPM between bezisterim and placebo patients following 30 weeks of treatment indicate statistically significant differences for the 2,154 DPMs using average promoter CpG methylation beta values as a surrogate for likely altered expression (Figure 2A). Five PBDPM genes met the significant FDR-adjusted cutoff $P < 0.001$ for increased DPM, suggesting potential outcomes associated with their decreased expression: *HOXA4, TYW3, CRYZ, B3GALT4,* and *CHPF* (refer to Table 1 for a description of activity associated with hypomethylation). *HOXA4* has epigenetic implications in neuropathy and cognitive decline; *TYW3/CRYZ* in IR and aberrant ubiquitination (in AD and amyotrophic lateral sclerosis); *B3GALT4* in AD-associated with dysregulated glycosylation, microglial neuroinflammation, and proinflammatory kinase cascades; and *CHPF* in prion disease, inflammation, and cognitive decline.

Additional PBDPM genes of significance meeting the FDR-adjusted $P > 0.001$ and $P < 0.05$ (n=442) are displayed in Figure 2B as $\geq$ +5% (n=427, potential decreased expression) or $\leq$

−5% (n=15, potential increased expression) DPM. Of 442 PBDPM genes, 432 had significantly increased DPM, indicating a presumed benefit with decreased expression. Only the top 14 genes with increased PBDPM are identified in red font. The top gene, *IKBKG*, which is essential for nuclear factor kappa B (NF-κB) activation and hypomethylation, is also linked to microglial neuroinflammation and cognitive decline in AD.

For 15 of the 18 genes with significantly decreased DPM, PBDPM gene are associated with presumed increased expression (Figure 2B, green) based on their known functions (Table 1). The top two genes in this group are *CDK16*, thought to enhance neuron survival through improved autophagy and decreased inflammatory gene expression, and *DUSP22*, an anti-inflammatory phosphatase that decreases kinase cascades.

Epigenetic age deceleration PBDPM genes were compared (bezisterim versus placebo) for effects on metabolic inflammation activities. Figure 3 relates age deceleration clock genes to other published activities associated with AD, aging, and diseases of aging. Red circles in Figure 3 indicate PBDPM in genes with increased DPM and known associations to inflammation; gray circles indicate PBDPM in genes with increased DPM and no identified association to inflammation; and green circles indicate PBDPM in genes with decreased DPM. Table 2 lists the relationship of genes to inflammation, and the number of shared associations. There were 45 genes identified from CpGs in EAA clocks with significant bezisterim-associated age deceleration. Of these, 39 (87%) were associated with inflammation. Overall, 249 of the genes with known associations to diseases of metabolic inflammation and aging that are captured by the EAA clocks were identified as PBDPM genes in the bezisterim group. Additional genes associated with cognition, diabetes, obesity, M1 polarization, kinase cascades, dysregulated lipids, glycolysis, dysregulated phosphoproteins, nominated aging and AD targets, chromatin remodeling, and TFs are listed in Supplement 1, Table S1.

Bezisterim was associated with PBDPM clock genes linked to plasma proteomics in AD, Parkinson's disease (PD), and frontotemporal dementia (FTD) (Ali et al., 2025). Also, microglial transcription levels were linked to PBDPM genes (Kosoy et al., 2025). Of 18 PBDPM genes linked to neurologic disease, higher DPM seen with bezisterim appears to translate to a dampening of those genes' deleterious effects. In addition, bezisterim might provide beneficial effects via a decrease in expression of *EFN4A* (associated with dementia), *SOAT1* (associated

with Braak pathology scores), and *SP140*, which are three clock PBDPM genes that have been reported to have alterations to AD microglial transcripts (Kosoy et al., 2025).

Seven clock EAA genes were identified as having increased PBDPM following bezisterim treatment associated with TFs. Three of those TFs (*RUNX2*, *STAT3*, and *TCF12*) were significantly associated with transcription of 43 of the 45 shared genes. This suggests that increases in DNAm of TF expression might compound the effects of decreased expression of target genes with increased DPM resulting from bezisterim treatment.

Associations between all 447 bezisterim PBDPM genes and metabolic inflammation, aging, and AD are shown in Figure 4. These associations indicate a sharing of PBDPM genes among the risk factors in Table S1 (Supplementalary File 1). Of the 447 shared genes, 354 (79%) were associated with inflammation. There were a total of 1,670 shared risks with bezisterim-associatied PBDPM genes. Similar to the findings in the shared clock gene matrix, shared PBDPM genes included 189 related to cognition, 156 to T2D and IR, 148 to obesity, 146 to M1 polarization, 143 to inflammatory kinase cascade genes, 120 to lipid dysregulation, 90 to glycolysis and Warburg effect genes, 76 to dysregulated phosphoproteins, 37 to nominated aging and AD risk targets, 75 to chromatin remodeling genes, and 78 to TFs. The potentially beneficial activities associated with all 447 PBDPM genes are referenced in Supplementalary File 3.

There was evidence of PBDPM genes overlapping with neurodegenerative diseases. In AD, PD, and FTD plasma, 150 PBDPM genes had significantly increased plasma concentrations (Ali et al., 2025) but DPM was significantly increased with bezisterim; only one (*UBE2C*) had significantly decreased AD and PD plasma concentrations but decreased DPM with bezisterim. Of these 151 genes, 106 were associated with potential improvements in AD plasma levels, 62 were associated with PD, and 34 were associated with FTD (Tables S2b, S24, S25, S26). There were also 50 genes with significantly increased microglial transcripts for AD dementia (30) or Braak pathology score (20) (Kosoy et al., 2025), but significantly increased DPM (Tables S1, S27, S28).

The potential of TF-compounding effects on gene expression was also seen in the larger matrix. A total of 437 of the 447 PBDPM genes were significantly associated with transcription by 39 of the 78 identified PBDPM TFs. Supplementalary File 1 contains a master table (Table S2a) and a master figure (Table S2b), which also contain the gene name and the DNAm information for each gene. Supplementalary File 2 contains 31 supplemental tables with

individual clock or trait sharing with all of the other parameters (Tables S3-S29), and the TF results for ChEA 2022 and ENCODE 2015 for all shared genes (Tables S30 and S31) and shared clock genes (Tables S32 and S33).

3.4. Bezisterim FDR gene sum of promoter methylation correlations with clinical measures

We further investigated the relationships between the sum of promoter methylation for each of the 447 genes for correlations with clinical measures from the prior study. We examined correlations with the 31 parameters, as shown in Supplementalary File 4, Table S34. Increased promotor methylation of 22 genes correlated to 42 significant associations (all improvements) between bezisterim and lower Alzheimer's Disease Composite Score (ADCOMS), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Clinical Global Impression of Change (CGIC), cholesterol, Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12), Global Statistical Glo (GST), triglycerides, waist-to-hip ratio (WHR), and weight (Supplementalary File 4, Table S35).

There were 25 correlations with higher Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores (improvement) in bezisterim patients that were significantly associated with increased promoter methylation (positive correlations). *SLCBA2-AS2*, known to be upregulated in aging and related to neurodegeneration, was correlated with lower C1q complement protein (improvement) with further benefit associated with lower DPM (−11%). This indicates that higher expressions of the antisense gene *SLCBA2-AS1* lead to potential benefits. A majority of the PBDPM genes (n=66) were associated with multiple neurologic (ADCOMS=7, ADCS-ADL=25, CDR-SB=10, CGIC=1, and GST=10) and metabolic (cholesterol, triglycerides, WHR, and weight) measures (Supplementary File 4, Table S35). Most of the clinical measure correlates (n=42) were associated with 11 PBDPM genes: *CDK2AP1*, *DGKZ*, *IL6R*, *JDP2*, *KLF7*, *NEU1*, *NRBP1*, *P2RX1*, *SAT2*, *TGFBR2*, and *TGIF1* (Supplementary File 4, Table S37).

Between-treatment-groups differences in the correlations between genes and clinical outcomes were evaluated by computing Z scores based on the R values for each correlation per group. There were statistically significant differences (Ps < 0.05) between the bezisterim and placebo groups for 47 of the gene-to-clinical outcome correlations that achieved statistical significance in the bezisterim group (Supplementary File 4, Table S39). Examples of the

bezisterim PBDPM gene correlations with neurologic measures are shown in Figure 5A. Placebo promoter methylation was uncorrelated in each case, and the z score *P* values were significant between bezisterim and placebo in each case. ADL improvement was positively correlated with *JMJD6* (R=0.83), while ADCOMS improvement was negatively correlated (R=−0.64) with lower *JDP2* expression (increased promotor methylation), genes associated with increased AD plasma proteomics (Ali et al., 2025). CGIC improvement was negatively correlated (R=−0.72) with *TMEM14C* promoter methylation (i.e., lower expression), a gene known to stimulate neuroinflammation (Yien et al., 2014). GST improvement (decrease) was negatively correlated with *SAT2* promoter methylation (i.e., lower expression; R=−0.70). CDR-SB improvement (decrease) was negatively correlated with *TGIF1* promoter methylation (i.e., lower expression; R=−0.68). Cog12 improvement (decrease) was negatively correlated with *NRBP1* DPM (i.e., lower expression) (R=−0.71). Decreased plasma cholesterol (improvement) was negatively correlated with *TIGD1* promoter methylation (R=−0.71). See Supplementary File 3 for more information regarding each gene's associated activities.

3.5. Placebo FDR gene sum of promoter methylation correlations with clinical measures

There were significant trends for differences (Z score P) between placebo and bezisterim Pearson R values for correlations of 13 genes (Supplementary File 4, Table S40). As shown in Table S36 (Supplementary File 4) and Figure 5B, in placebo patients, there were significant negative correlations of higher ADCOMS (R=−0.75), ADAS-Cog12 (R=−0.72), and GST (R=−0.74), with total promoter methylation of the AD biomarker glial fibrillary acidic protein (GFAP). GFAP was uncorrelated in bezisterim patients. For each gene, decreased promoter methylation (i.e., increased expression) was correlated with increased GFAP, which is associated with AD progression.

In placebo patients, there was one potentially beneficial correlation: ADCS-ADL scores were significantly negatively correlated (R=−0.75, *P* = 0.0009) with *LEPR* promoter methylation sum. *LEPR* was uncorrelated with neurologic assessments in bezisterim patients, but was negatively correlated with cholesterol (Table S35, higher promoter methylation with lower cholesterol).

As shown in Supplementary File 4, Table S38, and Figure 5B, *NINJ2* promoter methylation was correlated with increased ADCOMS (R=−0.73), Cog12 (R=−0.75), and GST

(R=−0.77). Increases in these clinical measures are associated with disease progression. Decreases in the sum of placebo promoter methylation compared to bezisterim patients might increase the risk of decline in cognitive assessments as shown in Figure 5.

In Figure 6, systolic blood pressure (SBP) in placebo patients was significantly positively correlated with six DPM genes (*CSNK1D*, *CTSL*, *ETV1*, *MTHFR*, *SMARCD2*, and *TUBA4A*). SBP was uncorrelated in bezisterim patients. There was an apparent DPM increase for these genes at lower SBPs (Figure 6). Bezisterim treatment was not associated with hypertension, but there was an apparent relative increase in total promoter methylation of each of the six genes at lower SBPs.

Of the 68 bezisterim-correlated genes, 84% were associated with inflammation; 10 of these were shared with reported increased AD plasma levels, and four were shared with reported increased microglial transcripts. For placebo-correlated genes, 100% were associated with inflammation (Supplementary File 4, Tables S41 and S42).

4. Discussion

4.1. Epigenetic clocks

Epigenetic aging clocks have provided insight into risk factors associated with diseases of aging (Horvath, 2015). The insight is limited, however, by the uncertain effect of methylation of a single CpG that might either increase or decrease expression depending on its location in or around a given gene. For the current analysis, the genes associated with significant bezisterim-associated age deceleration clock CpGs were identified across 13 aging clocks (Figure 1), each having a different focus: PCHorvath2 and PCHannum relate to principle components of biological aging; PCGrimAge links to principle components of mortality; IntrinClock is associated with aging independent of immune factors; DamAge relates to DNAm caused by injury, disease, and mortality; Stochastic Zang, Horvath, and PhenoAge are associated with random, aging-related DNAm; retroviral integration clocks (RetroClock and RetroClockV2) are associated with epigenetic changes in long interspersed transposable elements (e.g., LINE-1); organ-specific SystemsAge clocks are associated with epigenetic aging of Heart, Lung, and SystemsAge overall. These genes were cross-referenced with bezisterim-associated PBDPM genes having significant average CpG methylation differences based on multiple promoter

methylation sites. This DPM analysis may provide a higher probability of ascertaining the activity of various genes relevant to regulation of expression.

We identified 45 EAA clock genes with significant PBDPM. For the significant age deceleration of the PCHorvath2 EAA clock (Figure 1), there were nine DPM genes identified that were all associated with inflammation (Figure 3). Previously, we found correlations between the SkinBloodAge EAA scores (Horvath et al., 2018) at study completion for bezisterim patients and neurologic assessments (C. Y. Reading et al., 2025) There were no significant correlations for placebo patients. In this study, we found significant correlations of bezisterim PBDPM EAA clock genes with clinical measures in four EAA clock genes (Table S41): *NRBP1* from the DamAge EAA clock was correlated with ADCS-ADL, CDR-SB, GST, and ADCOMS; *MJD6* from the IntrinClock EAA was correlated with ADCS-ADL; *DGKZ* from the StocPhenoAge EAA was correlated with ADCS-ADL, CDR-SB, GST, and ADCOMS; and *IL12RB1* was correlated to triglycerides. There were no significant correlations between placebo DPM clock genes and neurologic assessments. The gene *CSNK1D* was represented in three EAA clocks (IntrinClock, StocZhang, and StocHorvath), and was correlated with SBP, which may be a risk for decreased cerebral perfusion.

4.2. Investigations of identified PBDPM genes

The overall patterns of genes identified in Figures 3 and 4 show sharing of associations with inflammatory, metabolic, and transcriptional dysregulation. Genes with relevant activities for aging and AD due to genetic mutations and single nucleotide polymorphisms were not emphasized in the shared gene analysis, since it is unlikely they would be represented at a level that would impact the conclusions from small clinical sample numbers.

4.3. Differences in promoter methylation

Of 11,322 genes, 2154 (19%) were found to have FDR-adjusted $P < 0.05$ significant DPM. Potentially beneficial effects of DPM were identified for the top five genes overall, and for 432 of the genes with increased DPM and 15 genes with decreased DPM (Figure 2). The significance of these findings supports a bona fide activity of bezisterim to enrich AD patients' DPM of genes in a potentially beneficial manner. For an unrelated gene set (SOMAscan and

OLINK disease proxy genes) (Gadd et al., 2022), there was 1/113 significant DPM genes. The difference is significant (Fisher Exact Test P = 2.2e-9).

The data from Figures 3 and 4 and Table 1 suggest broad functional associations between the DPM of specific genes and AD/aging risks, potentially identifying molecular changes associated with bezisterim-associated systems biology effects. For instance, Aβ and pTau DAMPs activate kinases that inhibit insulin signaling. (Berlanga-Acosta et al., 2020; Shaughness, Acs, Brabazon, Hockenbury, & Byrnes, 2020; Q. Zhang et al., 2018). Inflammation risk was the major shared trait and may represent the teleologic basis for the associations. Evolutionary control of responses to pathogens has selected for regulatory responses that eliminate the pathogen, terminate the response, and then resolve and repair damage associated with the process. This regulation is a double-edged sword, since metabolic diseases, including T2D and obesity, are associated with overnutrition, which is only recently epidemic, even as increased longevity allows for age-associated neurologic diseases such as AD and PD, conditions which are also evolutionarily recent. These conditions create DAMPs (e.g., glycosylated proteins, prion-like protein aggregates) that trigger metabolic inflammation, but resolution of the process is lacking since inflammatory responses increase, rather than eliminate, the DAMPs. Based on the PBDPM associations evident with genes associated with decreased M1 microglial and macrophage responses, and the requisite Warburg glycolysis effect, we can hypothesize that bezisterim may have an effect on homeostatic restoration in the face of metabolic and protein-aggregating inflammatory responses. Bezisterim decreased macrophage inflammatory responses, kinase cascades, and IR in diabetes models (M. Lu et al., 2010; T. Wang et al., 2010). In patients with impaired glucose tolerance and obesity, bezisterim treatment leads to increased insulin-stimulated glucose disposal, increased high-density lipoprotein (HDL) cholesterol, decreased C-reactive protein (CRP), and decreased IR (C. L. Reading, Stickney, et al., 2013) while improving insulin sensitivity, metabolic dysregulation, and hemoglobin-A1c (HbA1c) (C. L. Reading, Flores-Riveros, et al., 2013). In AD, bezisterim decreased glucose, cholesterol, and monocyte chemoattractant protein 1, and increased homeostatic model 2 insulin sensitivity and beta cell function with alterations in the monocyte methylome (C. Y. Reading et al., 2025). Data in Figures 3 and 4 and Table 1 for inflammation, kinase cascades, M1 polarization, and glycolysis suggest that bezisterim may alter the polarization of macrophages and microglia, inducing a shift

from an M1 pro-inflammatory state to an M2 restorative state. We reported that bezisterim appeared to alter the monocyte methylome in AD patients. (C. Y. Reading et al., 2025)

After inflammation, the second-most prevalent gene sharing was with cognition risks. There were 189 PBDPM genes associated with cognition (Figure 4).

The prior findings support the proposition that bezisterim may be altering the expression of genes impacting AD and cognition, inflammation, and dysregulated lipid metabolism. In this study, there were potentially beneficial changes of approximately 8% overall in 432 genes with increased DPM, and –11% overall in 15 genes with decreased DPM. This number may be an underestimation of the overall effect for four reasons: First, kinase cascades involved in signal transduction involve sequential phosphorylation of several kinases and targets (including nuclear factor κB [NF-κB], mitogen-activated protein kinase [MAPK], p28, and Jun N-terminal kinases [JNK], followed by phosphoprotein targets, including TFs), which may lead to compounding effects on the targets and TFs. Second, as shown in Figures 3 and 4, TFs with PBDPM are involved in the transcription of genes with PBDPM, again leading to compounding effects. Third, chromatin-remodeling genes with PBDPM alter access to the TFs with multiple PBDPM. Finally, TFs work in concert, suggesting that for multiple PBDPM gene TFs with potentially decreased expression, there may be a compounding effect on transcription at a promoter with multiple TF sites, with further impact if the site is for a PBDPM gene.

Systems biology citations for inflammatory mediators warn of a context dependency for a pro- or anti-inflammatory effect. Mechanisms of inflammatory processes in AD and aging may be elucidated by defining biomarkers of response to bezisterim. Since there were potentially beneficial responses in the AD study (C. Reading et al., 2025), we have focused on PBDPM genes. In the absence of clinically reported serious adverse events to date, we have not explored potentially deleterious DPM, and the definition would be tenuous since the context following bezisterim treatment is clearly different than placebo. In fact, the modulation of DPM may be involved in the safety profile, since an 8-11% increase or decrease in DPM has limited impact compared to complete inhibition, mutation, or knockout of a gene. Also, the number of nominated target genes in Figures 3 and 4 are smaller than other parameters, possibly since thorough inhibition of most genes can result in serious effects or diseases.

Data for PBDPM genes in Figure 4 are similar to those for PBDPM clock genes in Figure 3. The overall patterns show sharing of associations with inflammatory, metabolic, and

transcriptional dysregulation. For available plasma levels of PBDPM clock genes, 10 of 45 gene products were reported to be significantly increased in AD plasma, but had higher DPM with bezisterim, likely associated with decreased expression. For the overall shared genes, 105 of 433 PBDPM genes with increased methylation were reportedly significantly increased in plasma, and one of 15 PBDPM genes with decreased methylation was reportedly significantly decreased in plasma.

Although shared genes were based on bezisterim-associated DNA promoter methylation of genes, due to alternative splicing and post-translational modifications, proteoforms of the approximately 20,000 human protein-coding genes may exceed 10 times that number (Aebersold et al., 2018). Information regarding the extent of functional changes due to specific splicing alterations in AD is scarce (Koch, 2018). For instance, splice variants of *ADIPOR2* are associated with decreased amyloid; *FDPS* are associated with increased neuritic plaques; *LPCAT4* are associated with increased tangles; *PFPK* are associated with increases in neuritic plaques, tangles, and amyloid, while *SOD2* and *TMEM14C* link to increased tangles. These data suggest that splice variants may have altered effects from the normal message or protein on AD biomarkers, and thus also on risk factors.

4.4. Bezisterim gene sum of promoter methylation correlations

The sum of promoter CpG methylation for each of the PBDPM genes was analyzed for correlations with clinical measures from the previous clinical study (C. Reading et al., 2025). With bezisterim, we found evidence for 68 significant associations of PBDPM genes that correlated with neurologic assessments and clinical metabolic measures. While bezisterim correlates may characterize mechanisms and clinical activity, placebo correlates may help to define disease progression. This suggests that correlations between clinical measures and gene promoter expression may provide valuable prognostic information in a clinical setting, and also act as biomarkers of clinical response

4.5. Promoter gene sum of promoter methylation correlations with clinical measures

For placebo patients, there were significantly fewer relationships correlated to clinical measres (13) than with bezisterim patients (68). Independent of bezisterim, there were several sets of placebo promoter methylation correlations that might be potential biomarkers of AD.

For placebo GFAP correlations, three genes showed lower methylation associated with higher GFAP, indicating potential decline in the AD biomarker may be associated with inflammatory and disease activities. Decreased *GPD2* promoter methylation may stimulate inflammatory responses and M1 polarization (Langston et al., 2019), increase gluconeogenesis in T2D (Madiraju et al., 2014), and induce inflammation-stimulated glycolysis (J. Lu et al., 2020; Oh et al., 2024). Decreased *IRF3* methylation may increase microglial neuroinflammation (Herzog & Wallace, 1997), M1 polarization (N. Wang, Liang, & Zen, 2014), glycolysis (Yan et al., 2021), cognitive decline (Neupane et al., 2024), obesity (Kumari et al., 2016), inflammatory chromatin remodeling (Song et al., 2021), and T2D lipid dysregulation (H. Hu et al., 2020). Decreased *P2RX1* promoter methylation may increase Aß toxicity, microglial neuroinflammation, and excitotoxicity (Franke, Schepper, Illes, & Krugel, 2007; Godoy, Ramirez-Molina, & Fuentealba, 2019; Monif, Reid, Powell, Smart, & Williams, 2009), glycolysis, M1 polarization (X. Wang, Yuan, et al., 2021), T2D, and obesity (Cabral-Garcia et al., 2024).

Lower placebo DPM for *NINJ2* (expected higher expression) was correlated with AD progression through ADCOMS, ADAS-Cog12, and GST clinical measures, as evidenced by higher Z scores with placebo . Decreased *NINJ2* promoter methylation may increase microglial, macrophage, and endothelial neuroinflammation (Liu et al., 2025; Sorosina et al., 2022), as well as neurovascular risk (K. Lin et al., 2011).

For placebo, decreased promoter methylation (likely increased expression) for six genes (*MTHFR*, *SMARCD2*, *CSNK1D*, *CTSL*, *TUBA4A*, and *ETV1*) correlated with decreased SBP. There were apparent lower SBP Z scores for placebo compared to bezisterim patients (Figure 6). Increases in expression of these six genes are associated with inflammation and disease correlates. *MTHFR* metabolizes homocysteine, which may decrease BP (Skeete & DiPette, 2017) and contribute to the common pathogenesis of psychiatric diseases (Y. X. Zhang et al., 2022). *SMARCD2* expression is associated with inflammation, neutrophilia, and epigenetic histone chromatin remodeling (Foster, McCrary, Ross, & Wright, 2006; Gullett & Kanneganti, 2022; Priam et al., 2024). *CSNK1D* expression is associated with microglial neuroinflammation, cognitive decline, and kinase cascades (Benn & Dawson, 2020; Kramer, La Piana, & Whitmore, 1980; Martinez-Gonzalez et al., 2020; Sharma et al., 2024; P. Xu et al., 2019), and is increased in AD plasma (Ali et al., 2025). *CTSL* expression is associated with increased microglial

neuroinflammation, M1 polarization, Caspase 8, NF-κB, and GSK2beta activation (Fei et al., 2018; Tang et al., 2009; S. Xu, Zhang, Yang, Qian, & Xiao, 2018; H. Zhang, Qin, Yuan, Xiang, & Yu, 2025). *TUBA4A* expression is associated with microglial neuroinflammation and increased pTau (Hausrat et al., 2022). *ETV1* expression is associated with increased inflammation, CCL2-dysregulated MAPK phosphorylation, demethylase interaction, chromatin modeling, and TF activity (ETV1, 2025).

We previously reported imaging data from a 13-week open-label study of 23 patients with mild cognitive impairment and mild AD (Haroon et al., 2024). Bezisterim was associated with clinician-rated improvements in relative cerebral blood flow (rCBF) using arterial spin label imaging and blood-oxygen–dependent functional connectivity within the brain. rCBF is strongly correlated with fluorodeoxyglucose-positron emission tomography (FDG-PET) brain imaging and metabolic coupling in AD. The significant positive placebo correlations of SBP (Figure 6) reveal that in AD, the correlated genes may contribute to decreased central nervous system (CNS) perfusion (i.e., lower methylation of *CSNK1D*, *CTSL*, *ETV1*, *MTHFR*, *SMARCD2*, and *TUBA4A* may result in lower SBP and CNS perfusion). The trend toward lower Z scores for placebo SBP compared to bezisterim patients (Figure 6) suggests that bezisterim might improve rCBF and brain hypometabolism compared to placebo by altering the expression of genes that are covariates of perfusion.

For placebo, *LEPR* promoter methylation sum was negatively correlated with ADL Z scores, indicating that increased leptin receptors may be associated with improvements in activities of daily living. This may be a good example of context-dependent regulation in AD. *LEPR* has been associated with inflammation, M1 polarization (Y. Wang, Wan, & Hu, 2023), increased glycolysis (Y. Xu et al., 2020), kinase cascades (Park & Ahima, 2014), and dysregulated phosphoproteins (Gong et al., 2007). On the other hand, leptin receptor transcript levels are decreased in AD brains, and the leptin receptor protein is localized to neurofibrillary tangles, suggesting a severe discontinuity in the leptin signaling pathway (Bonda et al., 2014). *LEPR* promoter methylation sum was uncorrelated in bezisterim patients.

5. Conclusions

There is evidence that bezisterim may modulate epigenetic effects in a pattern associated with inflammatory responses that are related to diseases of aging. Bezisterim decreased EAA in a

total of 13 biological aging clocks shown to be associated with aging in general. In particular, bezisterim decreased EAA in three stochastic clocks, which are based on random epigenetic changes in aging, rather than clocks such as the DamAge and GrimAge clocks that are associated with effects of diseases of aging and mortality. Based on EAA clocks and evidence of correlations between potential gene expression differences and clinical responses for neurologic and metabolic measures, it is tempting to speculate that bezisterim may increase healthspan in general.

Promoter-wide methylation analysis used in this study may be beneficial when exploring conditions or treatments for healthspan or diseases of aging. While clocks based on differences in individual CpG methylation have been an immense advance in understanding aging, interpretations are limited without knowing the relationship of the individual CpGs to systems biology. Known potential markers of clinical benefit in bezisterim patients were associated with modulation of promoter-wide methylation of 447 age- and disease-related genes. The majority of these were associated with potentially beneficial regulation of inflammatory pathways. Although differences in promoter methylation of genes like *JMJD6* and *IKBKG* are exciting examples of bezisterim effects, the gestalt of the impact of all identified epigenetic differences between bezisterim and placebo underscore the need for a systems biology approach to understanding bezisterim activity.

The specifics of potential biomarkers that might be derived from this study await replication in a larger AD population. We are currently collecting DNAm data for bezisterim trials in PD (NCT06757010) and Long COVID (NCT06847191), with the possibility of understanding the generalizability of these findings in other neurodegeneration settings.

Acknowledgements

Editorial support was provided by *p*-value communications and funded by BioVie Inc.

Funding Statement

This study was funded by BioVie Inc.

Conflict of Interest Statement

During the conduct of the study, CR, JY, CA, PM, and JMP were employed by BioVie Inc., and VBD was employed by TruDiagnostic, Inc. SO'Q is a consultant to BioVie and is affiliated with Perissos, Inc., Wake Forest, NC.

Ethics Statement

The studies from which the DNAm data were obtained involving humans (NCT04669028; https://clinicaltrials.gov/study/NCT04669028?term=NCT04669028&rank=1) received IRB approval from ADVARRA (MOD01862543). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Data Availability Statement

The data that support the findings of this study are available in the main text and supplementary materials of the article.

Author Contribution Statement

CR designed analyses of differential promoter methylation genes; researched and curated literature relating to their potentially beneficial effects; composed overall manuscript; and designed and executed correlation analyses of promoter changes and clinical measures.

JY performed coding for methylation changes and statistical analyses, managed quality control of the data and analysis, and contributed to direction of the study.

PM and CA reviewed drafts, figures, and tables, and contributed various clarifying elements of the findings.

References

Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., . . . Zhang, B. (2018). How many human proteoforms are there? *Nature Chemical Biology, 14*(3), 206–214. https://dx.doi.org/10.1038/nchembio.2576

Agora, C. (n.d.). CELF1, cugbp elav-like family member 1. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000149187

Agora, F. (n.d.). FBXl16, f-box and leucine rich repeat protein 16. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000127585

Agora, J. (n.d.). JMJD6, jumonji domain containing 6, arginine demethylase and lysine hydroxylase. Retrieved from https://agora.adknowledgeportal.org/genes/ENSG00000070495

Ahlem, C. N., Kennedy, M. R., Page, T. M., Reading, C. L., White, S. K., McKenzie, J. J., . . . Frincke, J. M. (2011). Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β, a synthetic anti-inflammatory androstene. *International Journal of Clinical and Experimental Medicine, 4*(2), 119–135. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21686136

Ahmad, S., Elsherbiny, N. M., Bhatia, K., Elsherbini, A. M., Fulzele, S., & Liou, G. I. (2014). Inhibition of adenosine kinase attenuates inflammation and neurotoxicity in traumatic optic neuropathy. *Journal of Neuroimmunology, 277*(1–2), 96–104. https://dx.doi.org/10.1016/j.jneuroim.2014.10.006

Akrioti, E., Karamitros, T., Gkaravelas, P., Kouroupi, G., Matsas, R., & Taoufik, E. (2022). Early signs of molecular defects in iPSC-derived neural stems cells from patients with familial Parkinson's disease. *Biomolecules, 12*(7). https://dx.doi.org/10.3390/biom12070876

Alanazi, F. J., Alruwaili, A. N., Aldhafeeri, N. A., Ballal, S., Sharma, R., Debnath, S., . . . Imran, M. (2025). Pathological interplay of NF-κB and M1 macrophages in chronic inflammatory lung diseases. *Pathology, Research and Practice, 269*, 155903. https://dx.doi.org/10.1016/j.prp.2025.155903

Ali, M., Erabadda, B., Chen, Y., Xu, Y., Gong, K., Liu, M., . . . Cruchaga, C. (2025). Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases. *Nature Medicine, 31*(8), 2567–2577. https://dx.doi.org/10.1038/s41591-025-03833-1

An, N., Bassil, K., Al Jowf, G. I., Steinbusch, H. W. M., Rothermel, M., de Nijs, L., & Rutten, B. P. F. (2021). Dual-specificity phosphatases in mental and neurological disorders. *Progress in Neurobiology, 198*, 101906. https://dx.doi.org/10.1016/j.pneurobio.2020.101906

Anderegg, M. A., Gyimesi, G., Ho, T. M., Hediger, M. A., & Fuster, D. G. (2022). The less well-known little brothers: The SLC9B/NHA sodium proton exchanger subfamily-structure, function, regulation and potential drug-target approaches. *Frontiers in Physiology, 13*, 898508. https://dx.doi.org/10.3389/fphys.2022.898508

Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., & Irizarry, R. A. (2014). Minfi: A flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. *Bioinformatics, 30*(10), 1363–1369. https://dx.doi.org/10.1093/bioinformatics/btu049

Avram, S., Shaposhnikov, S., Buiu, C., & Mernea, M. (2014). Chondroitin sulfate proteoglycans: Structure-function relationship with implication in neural development and brain disorders. *BioMed Research International, 2014*, 642798. https://dx.doi.org/10.1155/2014/642798

Aykac, A., & Sehirli, A. O. (2020). The role of the SLC transporters protein in the neurodegenerative disorders. *Clinical Psychopharmacology and Neuroscience, 18*(2), 174–187. https://dx.doi.org/10.9758/cpn.2020.18.2.174

B3GALT4. (2025). B3galt4, beta-1,3-galactosyltransferase 4. Retrieved from https://www.ncbi.nlm.nih.gov/gene/8705

Bahl, S., & Seto, E. (2021). Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance. *Cellular and Molecular Life Sciences, 78*(2), 427–445. https://dx.doi.org/10.1007/s00018-020-03599-4

Bai, P., Mondal, P., Liu, Y., Gomm, A., Suen, C., Yang, L., . . . Wang, C. (2025). HDAC11 displays neuropathological alterations and offers as a novel drug target for Alzheimer's disease. *Alzheimer's & Dementia, 21*(3), e14616. https://dx.doi.org/10.1002/alz.14616

Bastie, C. C., Zong, H., Xu, J., Busa, B., Judex, S., Kurland, I. J., & Pessin, J. E. (2007). Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. *Cell Metabolism, 5*(5), 371–381. https://dx.doi.org/10.1016/j.cmet.2007.04.005

Begin, S. G., F.; Tchernof, A.; Deshais, Y.; Perusse, L.; Hould, F.S.; Lebel, S.; Marceau, P.; Vohl, M.C. (2016). The rare allele of DGKZ SNP rs10838599 is associated with variability in HDL-cholesterol levels among severely obese patients. *Integrative Obesity & Diabetes, 2*(2), 219–224. https://dx.doi.org/10.15761/IOD.1000148

Benn, C. L., & Dawson, L. A. (2020). Clinically precedented protein kinases: Rationale for their use in neurodegenerative disease. *Frontiers in Aging Neuroscience, 12*, 242. https://dx.doi.org/10.3389/fnagi.2020.00242

Benziane, B., Borg, M. L., Tom, R. Z., Riedl, I., Massart, J., Bjornholm, M., . . . Zierath, J. R. (2017). DGK☐ deficiency protects against peripheral insulin resistance and improves energy metabolism. *Journal of Lipid Research, 58*(12), 2324–2333. https://dx.doi.org/10.1194/jlr.M079723

Berlanga-Acosta, J., Guillen-Nieto, G., Rodriguez-Rodriguez, N., Bringas-Vega, M. L., Garcia-Del-Barco-Herrera, D., Berlanga-Saez, J. O., . . . Valdes-Sosa, P. A. (2020). Insulin resistance at the crossroad of Alzheimer disease pathology: A review. *Frontiers in Endocrinology, 11*, 560375. https://dx.doi.org/10.3389/fendo.2020.560375

Bi, L., Ren, Y., Feng, M., Meng, P., Wang, Q., Chen, W., . . . Wang, Y. (2021). HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. *Cancer Research, 81*(8), 2015–2028. https://dx.doi.org/10.1158/0008-5472.CAN-20-3044

Boks, M. P., Houtepen, L. C., Xu, Z., He, Y., Ursini, G., Maihofer, A. X., . . . Kahn, R. S. (2018). Genetic vulnerability to DUSP22 promoter hypermethylation is involved in the relation between in utero famine exposure and schizophrenia. *NPJ Schizophrenia, 4*(1), 16. https://dx.doi.org/10.1038/s41537-018-0058-4

Bonda, D. J., Stone, J. G., Torres, S. L., Siedlak, S. L., Perry, G., Kryscio, R., . . . Lee, H. G. (2014). Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance. *Journal of Neurochemistry, 128*(1), 162–172. https://dx.doi.org/10.1111/jnc.12380

Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer's disease: Causes and treatment. *Molecules, 25*(24). https://dx.doi.org/10.3390/molecules25245789

Cabral-Garcia, G. A., Cruz-Munoz, J. R., Valdez-Morales, E. E., Barajas-Espinosa, A., Linan-Rico, A., & Guerrero-Alba, R. (2024). Pharmacology of P2X receptors and their possible

therapeutic potential in obesity and diabetes. *Pharmaceuticals (Basel, Switzerland), 17*(10). https://dx.doi.org/10.3390/ph17101291

Cao, J., Sun, L., Aramsangtienchai, P., Spiegelman, N. A., Zhang, X., Huang, W., . . . Lin, H. (2019). HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. *Proceedings of the National Academy of Sciences of the United States of America, 116*(12), 5487–5492. https://dx.doi.org/10.1073/pnas.1815365116

Chang, Y. H., Tseng, Y. H., Wang, J. M., Tsai, Y. S., Liu, X. L., & Huang, H. S. (2024). Phosphorylation of TG-interacting factor 1 at carboxyl-terminal sites in response to insulin regulates adipocyte differentiation. *FEBS Letters, 598*(8), 945–955. https://dx.doi.org/10.1002/1873-3468.14849

Chen, C. W., Tsao, N., Zhang, W., & Chang, Z. F. (2020). NME3 regulates mitochondria to reduce ROS-mediated genome instability. *International Journal of Molecular Sciences, 21*(14). https://dx.doi.org/10.3390/ijms21145048

Chen, H., Xie, C., Chen, Q., & Zhuang, S. (2022). HDAC11, an emerging therapeutic target for metabolic disorders. *Frontiers in Endocrinology, 13*, 989305. https://dx.doi.org/10.3389/fendo.2022.989305

Chitra, S., Nalini, G., & Rajasekhar, G. (2012). The ubiquitin proteasome system and efficacy of proteasome inhibitors in diseases. *International Journal of Rheumatic Diseases, 15*(3), 249–260. https://dx.doi.org/10.1111/j.1756-185X.2012.01737.x

Chow, H. M., Shi, M., Cheng, A., Gao, Y., Chen, G., Song, X., . . . Herrup, K. (2019). Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. *Nature Neuroscience, 22*(11), 1806–1819. https://dx.doi.org/10.1038/s41593-019-0505-1

Citron, B. A., Saykally, J. N., Cao, C., Dennis, J. S., Runfeldt, M., & Arendash, G. W. (2015). Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. *American Journal of Neurodegenerative Disease, 4*(2), 40–48. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26807343

Dalmas, E., Toubal, A., Alzaid, F., Blazek, K., Eames, H. L., Lebozec, K., . . . Venteclef, N. (2015). Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. *Nature Medicine, 21*(6), 610–618. https://dx.doi.org/10.1038/nm.3829

Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018). Disease-associated microglia: A universal immune sensor of neurodegeneration. *Cell, 173*(5), 1073–1081. https://dx.doi.org/10.1016/j.cell.2018.05.003

Deczkowska, A., Matcovitch-Natan, O., Tsitsou-Kampeli, A., Ben-Hamo, S., Dvir-Szternfeld, R., Spinrad, A., . . . Schwartz, M. (2017). Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. *Nature Communications, 8*(1), 717. https://dx.doi.org/10.1038/s41467-017-00769-0

Deisl, C., Anderegg, M., Albano, G., Luscher, B. P., Cerny, D., Soria, R., . . . Fuster, D. G. (2016). Loss of sodium/hydrogen exchanger NHA2 exacerbates obesity- and aging-induced glucose intolerance in mice. *PloS One, 11*(9), e0163568. https://dx.doi.org/10.1371/journal.pone.0163568

Elliott, P. J., Zollner, T. M., & Boehncke, W. H. (2003). Proteasome inhibition: A new anti-inflammatory strategy. *Journal of Molecular Medicine (Berlin, Germany), 81*(4), 235–245. https://dx.doi.org/10.1007/s00109-003-0422-2

Erbilgin, A., Seldin, M. M., Wu, X., Mehrabian, M., Zhou, Z., Qi, H., . . . Lusis, A. J. (2018). Transcription factor Zhx2 deficiency reduces atherosclerosis and promotes macrophage apoptosis in mice. *Arteriosclerosis, Thrombosis, and Vascular Biology, 38*(9), 2016–2027. https://dx.doi.org/10.1161/ATVBAHA.118.311266

ETV1. (2025). Ets variant transcription factor 1. Retrieved from https://www.ncbi.nlm.nih.gov/gene/2115

Fang, Y., Lu, Z. H., Liu, B. Z., Li, N., Yang, M. Z., & Wang, P. (2023). IRF5 promotes glycolysis in the progression of hepatocellular carcinoma and is regulated by TRIM35. *Journal of Digestive Diseases, 24*(8–9), 480–490. https://dx.doi.org/10.1111/1751-2980.13218

Fei, Y., Xiong, Y., Shen, X., Zhao, Y., Zhu, Y., Wang, L., & Liang, Z. (2018). Cathepsin L promotes ionizing radiation-induced U251 glioma cell migration and invasion through regulating the SK-3β/CUX1 pathway. *Cellular Signalling, 44*, 62–71. https://dx.doi.org/10.1016/j.cellsig.2018.01.012

Fortin, J. P., Triche, T. J., Jr., & Hansen, K. D. (2017). Preprocessing, normalization and integration of the illumina humanmethylationepic array with minfi. *Bioinformatics, 33*(4), 558–560. https://dx.doi.org/10.1093/bioinformatics/btw691

Foster, K. S., McCrary, W. J., Ross, J. S., & Wright, C. F. (2006). Members of the hSWI/SNF chromatin remodeling complex associate with and are phosphorylated by protein kinase B/Akt. *Oncogene, 25*(33), 4605–4612. https://dx.doi.org/10.1038/sj.onc.1209496

Franke, H., Schepper, C., Illes, P., & Krugel, U. (2007). Involvement of P2X and P2Y receptors in microglial activation in vivo. *Purinergic Signal, 3*(4), 435–445. https://dx.doi.org/10.1007/s11302-007-9082-y

Fraschilla, I., & Jeffrey, K. L. (2020). The speckled protein (SP) family: Immunity's chromatin readers. *Trends in Immunology, 41*(7), 572–585. https://dx.doi.org/10.1016/j.it.2020.04.007

Friend, C. J. (2023). TGIF1 physiological levels limit ß-cell distress and neonatal diabetes. Retrieved from https://dx.doi.org/10.25772/J98Y-M292

Gadd, D. A., Hillary, R. F., McCartney, D. L., Zaghlool, S. B., Stevenson, A. J., Cheng, Y., . . . Marioni, R. E. (2022). Epigenetic scores for the circulating proteome as tools for disease prediction. *eLife, 11*. https://dx.doi.org/10.7554/eLife.71802

Gao, X., Chen, Q., Yao, H., Tan, J., Liu, Z., Zhou, Y., & Zou, Z. (2022). Epigenetics in Alzheimer's disease. *Frontiers in Aging Neuroscience, 14*, 911635. https://dx.doi.org/10.3389/fnagi.2022.911635

Garwain, O., Yerramilli, V. S., Romero, K., & Scarlata, S. (2020). The Gαq/phospholipase Cβ signaling system represses tau aggregation. *Cellular Signalling, 71*, 109620. https://dx.doi.org/10.1016/j.cellsig.2020.109620

GDP2. (2024). Gpd2, glycerol-3-phosphate dehydrogenase 2. Retrieved from https://omim.org/entry/138430

Ge, C., Tan, J., Dai, X., Kuang, Q., Zhong, S., Lai, L., . . . Xu, M. (2022). Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK. *Nature Communications, 13*(1), 5945. https://dx.doi.org/10.1038/s41467-022-33493-5

Godoy, P. A., Ramirez-Molina, O., & Fuentealba, J. (2019). Exploring the role of P2X receptors in Alzheimer's disease. *Frontiers in Pharmacology, 10*, 1330. https://dx.doi.org/10.3389/fphar.2019.01330

Gong, Y., Ishida-Takahashi, R., Villanueva, E. C., Fingar, D. C., Munzberg, H., & Myers, M. G., Jr. (2007). The long form of the leptin receptor regulates STAT5 and ribosomal protein S6

via alternate mechanisms. *Journal of Biological Chemistry, 282*(42), 31019–31027. https://dx.doi.org/10.1074/jbc.M702838200

Guglietti, B., Sivasankar, S., Mustafa, S., Corrigan, F., & Collins-Praino, L. E. (2021). Fyn kinase activity and its role in neurodegenerative disease pathology: A potential universal target? *Molecular Neurobiology, 58*(11), 5986–6005. https://dx.doi.org/10.1007/s12035-021-02518-3

Gullett, J. M., & Kanneganti, T. D. (2022). A BAF-fling connection to RIPK1. *Cell Research, 32*(8), 709–710. https://dx.doi.org/10.1038/s41422-022-00688-w

Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., . . . Zhang, K. (2013). Genome-wide methylation profiles reveal quantitative views of human aging rates. *Molecular Cell, 49*(2), 359–367. https://dx.doi.org/10.1016/j.molcel.2012.10.016

Haroon, J., Jordan, K., Mahdavi, K., Rindner, E., Becerra, S., Surya, J. R., . . . Jordan, S. (2024). A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias. *Medicine (Baltimore), 103*(30), e39027. https://dx.doi.org/10.1097/MD.0000000000039027

Hausrat, T. J., Janiesch, P. C., Breiden, P., Lutz, D., Hoffmeister-Ullerich, S., Hermans-Borgmeyer, I., . . . Kneussel, M. (2022). Disruption of tubulin-alpha4a polyglutamylation prevents aggregation of hyper-phosphorylated tau and microglia activation in mice. *Nature Communications, 13*(1), 4192. https://dx.doi.org/10.1038/s41467-022-31776-5

Hayashi, H., Kimura, N., Yamaguchi, H., Hasegawa, K., Yokoseki, T., Shibata, M., . . . Yanagisawa, K. (2004). A seed for Alzheimer amyloid in the brain. *Journal of Neuroscience, 24*(20), 4894–4902. https://dx.doi.org/10.1523/JNEUROSCI.0861-04.2004

He, X., Nie, Y., Zhou, H., Hu, R., Li, Y., He, T., . . . Liu, M. (2021). Structural insight into the binding of TGIF1 to SIN3A PAH2 domain through a C-terminal amphipathic helix. *International Journal of Molecular Sciences, 22*(23). https://dx.doi.org/10.3390/ijms222312631

Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., . . . Kummer, M. P. (2015). Neuroinflammation in Alzheimer's disease. *Lancet Neurology, 14*(4), 388–405. https://dx.doi.org/10.1016/S1474-4422(15)70016-5

Herzog, A. R., & Wallace, R. B. (1997). Measures of cognitive functioning in the ahead study. *Journals of Gerontology. Series B: Psychological Sciences and Social Sciences, 52*, 37–48. https://dx.doi.org/10.1093/geronb/52b.special_issue.37

Higgins-Chen, A. T., Thrush, K. L., Wang, Y., Minteer, C. J., Kuo, P. L., Wang, M., . . . Levine, M. E. (2022). A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. *Nature Aging, 2*(7), 644–661. https://dx.doi.org/10.1038/s43587-022-00248-2

Hneino, M., Blirando, K., Buard, V., Tarlet, G., Benderitter, M., Hoodless, P., . . . Milliat, F. (2012). The TG-interacting factor TGIF1 regulates stress-induced proinflammatory phenotype of endothelial cells. *Journal of Biological Chemistry, 287*(46), 38913–38921. https://dx.doi.org/10.1074/jbc.M112.388389

Hoff, S., Epting, D., Falk, N., Schroda, S., Braun, D. A., Halbritter, J., . . . Lienkamp, S. S. (2018). The nucleoside-diphosphate kinase NME3 associates with nephronophthisis proteins and is required for ciliary function during renal development. *Journal of Biological Chemistry, 293*(39), 15243–15255. https://dx.doi.org/10.1074/jbc.RA117.000847

Horvath, S. (2013). DNA methylation age of human tissues and cell types. *Genome Biology, 14*(10), R115. https://dx.doi.org/10.1186/gb-2013-14-10-r115

Horvath, S. (2015). Erratum to: DNA methylation age of human tissues and cell types. *Genome Biology, 16*(1), 96. https://dx.doi.org/10.1186/s13059-015-0649-6

Horvath, S., Oshima, J., Martin, G. M., Lu, A. T., Quach, A., Cohen, H., . . . Raj, K. (2018). Epigenetic clock for skin and blood cells applied to Hutchinson Gilford progeria syndrome and ex vivo studies. *Aging, 10*(7), 1758–1775. https://dx.doi.org/10.18632/aging.101508

Hou, P., Liu, G., Zhao, Y., Shi, Z., Zheng, Q., Bu, G., . . . Zhang, Y. W. (2015). Role of copper and the copper-related protein CUTA in mediating APP processing and Aβ generation. *Neurobiology of Aging, 36*(3), 1310–1315. https://dx.doi.org/10.1016/j.neurobiolaging.2014.12.005

Howie, H., Rijal, C. M., & Ressler, K. J. (2019). A review of epigenetic contributions to post-traumatic stress disorder. *Dialogues in Clinical Neuroscience, 21*(4), 417–428. https://dx.doi.org/10.31887/DCNS.2019.21.4/kressler

Hu, H. Q., Qiao, J. T., Liu, F. Q., Wang, J. B., Sha, S., He, Q., . . . Hou, X. G. (2020). The STING-IRF3 pathway is involved in lipotoxic injury of pancreatic beta cells in type 2 diabetes. *Molecular and Cellular Endocrinology, 518*, 110890. https://dx.doi.org/10.1016/j.mce.2020.110890

Hu, Y. J., Belaghzal, H., Hsiao, W. Y., Qi, J., Bradner, J. E., Guertin, D. A., . . . Imbalzano, A. N. (2015). Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. *Nucleic Acids Research, 43*(16), 7790–7804. https://dx.doi.org/10.1093/nar/gkv645

Huynh, M. B., Ouidja, M. O., Chantepie, S., Carpentier, G., Maiza, A., Zhang, G., . . . Papy-Garcia, D. (2019). Glycosaminoglycans from Alzheimer's disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau. *PloS One, 14*(1), e0209573. https://dx.doi.org/10.1371/journal.pone.0209573

ISOC2. (2025). Isochorismatase domain containing 2. Retrieved from https://maayanlab.cloud/Harmonizome/gene/ISOC2#:~:text=Collectively%2C%20these%20studies%20indicate%20that,cycle%20control%20and%20mitochondrial%20integrity

Jin, R., Chan, A. K. Y., Wu, J., & Lee, T. M. C. (2022). Relationships between inflammation and age-related neurocognitive changes. *International Journal of Molecular Sciences, 23*(20). https://dx.doi.org/10.3390/ijms232012573

Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., Sowmiya, S., . . . Prajapati, B. G. (2025). Effect of neuroinflammation on the progression of Alzheimer's disease and its significant ramifications for novel anti-inflammatory treatments. *IBRO Neuroscience Reports, 18*, 771–782. https://dx.doi.org/10.1016/j.ibneur.2025.05.005

Kang, J., Jia, T., Linli, Z., Li, Y., Cheng, W., Guo, S., & Feng, J. (2022). Association between obesity, brain atrophy and accelerated brain aging and their genetic mechanisms. *Health Sciences*. https://dx.doi.org/10.1101/2022.12.30.22284052

Karaky, M., Fedetz, M., Potenciano, V., Andres-Leon, E., Codina, A. E., Barrionuevo, C., . . . Matesanz, F. (2018). SP140 regulates the expression of immune-related genes associated with multiple sclerosis and other autoimmune diseases by NF-κB inhibition. *Human Molecular Genetics, 27*(23), 4012–4023. https://dx.doi.org/10.1093/hmg/ddy284

Kim, Y. J., Zhao, Y., Myung, J. K., Yi, J. M., Kim, M. J., & Lee, S. J. (2021). Suppression of breast cancer progression by FBXl16 via oxygen-independent regulation of HIF1α stability. *Cell Reports, 37*(8), 109996. https://dx.doi.org/10.1016/j.celrep.2021.109996

Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease. *Alzheimer's & Dementia (New York, N. Y.), 4*, 575–590. https://dx.doi.org/10.1016/j.trci.2018.06.014

Koch, L. (2018). Altered splicing in Alzheimer transcriptomes. *Nature Reviews Genetics, 19*(12), 738–739. https://dx.doi.org/10.1038/s41576-018-0064-4

Kosoy, R., Fullard, J. F., Bendl, J., Kleopoulos, S. P., Shao, Z., Argyriou, S., . . . Roussos, P. (2025). Alzheimer's disease transcriptional landscape in ex vivo human microglia. *Nature Neuroscience, 28*(9), 1830–1843. https://dx.doi.org/10.1038/s41593-025-02020-2

Kracht, M., Muller-Ladner, U., & Schmitz, M. L. (2020). Mutual regulation of metabolic processes and proinflammatory NF-κB signaling. *Journal of Allergy and Clinical Immunology, 146*(4), 694–705. https://dx.doi.org/10.1016/j.jaci.2020.07.027

Kramer, K. K., La Piana, F. G., & Whitmore, P. V. (1980). Enucleation with stabilization of intraocular pressure in the treatment of uveal melanomas. *Ophthalmic Surgery, 11*(1), 39–43. https://www.ncbi.nlm.nih.gov/pubmed/7360493

Krausgruber, T., Blazek, K., Smallie, T., Alzabin, S., Lockstone, H., Sahgal, N., . . . Udalova, I. A. (2011). IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. *Nature Immunology, 12*(3), 231–238. https://dx.doi.org/10.1038/ni.1990

Kumari, M., Wang, X., Lantier, L., Lyubetskaya, A., Eguchi, J., Kang, S., . . . Rosen, E. D. (2016). IRF3 promotes adipose inflammation and insulin resistance and represses browning. *Journal of Clinical Investigation, 126*(8), 2839–2854. https://dx.doi.org/10.1172/JCI86080

Langston, P. K., Nambu, A., Jung, J., Shibata, M., Aksoylar, H. I., Lei, J., . . . Horng, T. (2019). Glycerol phosphate shuttle enzyme GPD2 regulates macrophage inflammatory responses. *Nature Immunology, 20*(9), 1186–1195. https://dx.doi.org/10.1038/s41590-019-0453-7

Lee, T. W., Kwon, H., Zong, H., Yamada, E., Vatish, M., Pessin, J. E., & Bastie, C. C. (2013). Fyn deficiency promotes a preferential increase in subcutaneous adipose tissue mass and decreased visceral adipose tissue inflammation. *Diabetes, 62*(5), 1537–1546. https://dx.doi.org/10.2337/db12-0920

Li, H., Zheng, J., Xu, Q., Yang, Y., Zhou, J., Guo, X., . . . Wu, C. (2023). Hepatocyte adenosine kinase promotes excessive fat deposition and liver inflammation. *Gastroenterology, 164*(1), 134–146. https://dx.doi.org/10.1053/j.gastro.2022.09.027

Li, P., Zhu, X., Huang, C., Tian, S., Li, Y., Qiao, Y., . . . Tian, D. (2025). Effects of obesity on aging brain and cognitive decline: A cohort study from the UK Biobank. *IBRO Neuroscience Reports, 18*, 148–157. https://dx.doi.org/10.1016/j.ibneur.2025.01.001

Li, Q. S., Vasanthakumar, A., Davis, J. W., Idler, K. B., Nho, K., Waring, J. F., . . . Alzheimer's Disease Neuroimaging, I. (2021). Association of peripheral blood DNA methylation level with Alzheimer's disease progression. *Clinical Epigenetics, 13*(1), 191. https://dx.doi.org/10.1186/s13148-021-01179-2

Liao, W. C., Yen, H. R., Chen, C. H., Chu, Y. H., Song, Y. C., Tseng, T. J., & Liu, C. H. (2021). CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. *American Journal of Cancer Research, 11*(3), 812–826. https://www.ncbi.nlm.nih.gov/pubmed/33791155

Lin, K. P., Chen, S. Y., Lai, L. C., Huang, Y. L., Chen, J. H., Chen, T. F., . . . Chen, Y. C. (2011). Genetic polymorphisms of a novel vascular susceptibility gene, Ninjurin2 (NINJ2), are associated with a decreased risk of Alzheimer's disease. *PloS One, 6*(6), e20573. https://dx.doi.org/10.1371/journal.pone.0020573

Lin, Y., Qiu, T., Wei, G., Que, Y., Wang, W., Kong, Y., . . . Chen, X. (2022). Role of histone post-translational modifications in inflammatory diseases. *Frontiers in Immunology, 13*, 852272. https://dx.doi.org/10.3389/fimmu.2022.852272

Liu, S., He, Y., Chen, H., Zhao, W., Xu, H., Bai, T., & Feng, J. (2025). SLAMF8 and NINJ2 promote neuroinflammation and oxidative stress through TLR4 NF kappa B pathway in Alzheimer's disease. *Scientific Reports, 15*(1), 17501. https://dx.doi.org/10.1038/s41598-025-02097-6

Londhe, P., Yu, P. Y., Ijiri, Y., Ladner, K. J., Fenger, J. M., London, C., . . . Guttridge, D. C. (2018). Classical NF-κB metabolically reprograms sarcoma cells through regulation of hexokinase 2. *Frontiers in Oncology, 8*, 104. https://dx.doi.org/10.3389/fonc.2018.00104

Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., . . . Horvath, S. (2019). DNA methylation grimage strongly predicts lifespan and healthspan. *Aging, 11*(2), 303–327. https://dx.doi.org/10.18632/aging.101684

Lu, J., Xu, Z., Duan, H., Ji, H., Zhen, Z., Li, B., . . . Zhang, R. (2020). Tumor-associated macrophage interleukin- β promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells. *Cancer Science, 111*(6), 1979–1990. https://dx.doi.org/10.1111/cas.14408

Lu, M., Patsouris, D., Li, P., Flores-Riveros, J., Frincke, J. M., Watkins, S., . . . Olefsky, J. M. (2010). A new antidiabetic compound attenuates inflammation and insulin resistance in zucker diabetic fatty rats. *American Journal of Physiology: Endocrinology and Metabolism, 298*(5), E1036–1048. https://dx.doi.org/10.1152/ajpendo.00668.2009

Lundstrom, K., Hromic-Jahjefendic, A., Bilajac, E., Aljabali, A. A. A., Baralic, K., Sabri, N. A., . . . Barh, D. (2023). COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. *Cellular Signalling, 101*, 110495. https://dx.doi.org/10.1016/j.cellsig.2022.110495

Ma, M., Jiang, W., & Zhou, R. (2024). Damps and damp-sensing receptors in inflammation and diseases. *Immunity, 57*(4), 752–771. https://dx.doi.org/10.1016/j.immuni.2024.03.002

Ma, R., Zhang, X., Li, R., Dong, X., Wang, W., Jiang, Q., . . . Wang, J. (2025). PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2. *Journal of Virology, 99*(3), e0208524. https://dx.doi.org/10.1128/jvi.02085-24

Ma, Y., Wang, W., Liu, S., Qiao, X., Xing, Y., Zhou, Q., & Zhang, Z. (2023). Epigenetic regulation of neuroinflammation in Alzheimer's disease. *Cells, 13*(1). https://dx.doi.org/10.3390/cells13010079

Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X. M., Braddock, D. T., Albright, R. A., . . . Shulman, G. I. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. *Nature, 510*(7506), 542–546. https://dx.doi.org/10.1038/nature13270

Maqbool, A., Lattke, M., Wirth, T., & Baumann, B. (2013). Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. *Molecular Neurodegeneration, 8*, 40. https://dx.doi.org/10.1186/1750-1326-8-40

Martinez-Gonzalez, L., Rodriguez-Cueto, C., Cabezudo, D., Bartolome, F., Andres-Benito, P., Ferrer, I., . . . de Lago, E. (2020). Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. *Scientific Reports, 10*(1), 4449. https://dx.doi.org/10.1038/s41598-020-61265-y

Matsubara, T., Nishihara, M., Yasumori, H., Nakai, M., Yanagisawa, K., & Sato, T. (2017). Size and shape of amyloid fibrils induced by ganglioside nanoclusters: Role of sialyl oligosaccharide in fibril formation. *Langmuir, 33*(48), 13874–13881. https://dx.doi.org/10.1021/acs.langmuir.7b02091

Meen, A. J., Doncheva, A. I., Bottcher, Y., Dankel, S. N., Hoffmann, A., Bluher, M., . . . Kolset, S. O. (2023). Obesity is associated with distorted proteoglycan expression in adipose tissue. *International Journal of Molecular Sciences, 24*(8). https://dx.doi.org/10.3390/ijms24086884

Merchant, J. P., Zhu, K., Henrion, M. Y. R., Zaidi, S. S. A., Lau, B., Moein, S., . . . Chang, R. (2023). Predictive network analysis identifies JMJD6 and other potential key drivers in Alzheimer's disease. *Communications Biology, 6*(1), 503. https://dx.doi.org/10.1038/s42003-023-04791-5

Merida, I., Arranz-Nicolas, J., Rodriguez-Rodriguez, C., & Avila-Flores, A. (2019). Diacylglycerol kinase control of protein kinase c. *Biochemical Journal, 476*(8), 1205–1219. https://dx.doi.org/10.1042/BCJ20180620

Meur, S., & Karati, D. (2025). Fyn kinase in Alzheimer's disease: Unraveling molecular mechanisms and therapeutic implications. *Molecular Neurobiology, 62*(1), 643–660. https://dx.doi.org/10.1007/s12035-024-04286-2

Monif, M., Reid, C. A., Powell, K. L., Smart, M. L., & Williams, D. A. (2009). The P2X7 receptor drives microglial activation and proliferation: A trophic role for P2X7R pore. *Journal of Neuroscience, 29*(12), 3781–3791. https://dx.doi.org/10.1523/JNEUROSCI.5512-08.2009

Morel, M., & Long, W. (2024). FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. *Molecular Oncology, 18*(3), 762–777. https://dx.doi.org/10.1002/1878-0261.13554

Ndhlovu, L. C., Bendall, M. L., Dwaraka, V., Pang, A. P. S., Dopkins, N., Carreras, N., . . . Corley, M. J. (2024). Retro-age: A unique epigenetic biomarker of aging captured by DNA methylation states of retroelements. *Aging Cell, 23*(10), e14288. https://dx.doi.org/10.1111/acel.14288

Neupane, C., Sharma, R., Gao, F. F., Pham, T. L., Kim, Y. S., Yoon, B. E., . . . Park, J. B. (2024). Role of the STING-IRF3 pathway in ambient GABA homeostasis and cognitive function. *Journal of Neuroscience, 44*(41). https://dx.doi.org/10.1523/JNEUROSCI.1810-23.2024

Neutzner, M., Kohler, C., Frank, S., Killer, H. E., & Neutzner, A. (2023). Impact of aging on meningeal gene expression. *Fluids Barriers CNS, 20*(1), 12. https://dx.doi.org/10.1186/s12987-023-00412-9

Nunez-Alvarez, Y., & Suelves, M. (2022). HDAC11: A multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. *FEBS Journal, 289*(10), 2771–2792. https://dx.doi.org/10.1111/febs.15895

Oh, S., Jo, S., Bajzikova, M., Kim, H. S., Dao, T. T. P., Rohlena, J., . . . Park, S. (2023). Non-bioenergetic roles of mitochondrial GPD2 promote tumor progression. *Theranostics, 13*(2), 438–457. https://dx.doi.org/10.7150/thno.75973

Oh, S., Mai, X. L., Kim, J., de Guzman, A. C. V., Lee, J. Y., & Park, S. (2024). Glycerol 3-phosphate dehydrogenases (1 and 2) in cancer and other diseases. *Experimental and Molecular Medicine, 56*(5), 1066–1079. https://dx.doi.org/10.1038/s12276-024-01222-1

Oikawa, N., Matsubara, T., Fukuda, R., Yasumori, H., Hatsuta, H., Murayama, S., . . . Yanagisawa, K. (2015). Imbalance in fatty-acid-chain length of gangliosides triggers Alzheimer amyloid deposition in the precuneus. *PloS One, 10*(3), e0121356. https://dx.doi.org/10.1371/journal.pone.0121356

Pai, P., & Sukumar, S. (2020). HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology. *Biochimica Biophysica Acta Reviews on Cancer, 1874*(2), 188450. https://dx.doi.org/10.1016/j.bbcan.2020.188450

Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M., Kam, T. I., Jin, H., . . . Kanthasamy, A. (2019). Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia. *Journal of Experimental Medicine, 216*(6), 1411–1430. https://dx.doi.org/10.1084/jem.20182191

Pantaleo, E., Monaco, A., Amoroso, N., Lombardi, A., Bellantuono, L., Urso, D., . . . Bellotti, R. (2022). A machine learning approach to Parkinson's disease blood transcriptomics. *Genes (Basel), 13*(5). https://dx.doi.org/10.3390/genes13050727

Park, H. K., & Ahima, R. S. (2014). Leptin signaling. *F1000Prime Reports, 6*, 73. https://dx.doi.org/10.12703/P6-73

Parker, D., Davidson, K., Osmulski, P. A., Gaczynska, M., & Pickering, A. M. (2025). Proteasome augmentation mitigates age-related cognitive decline in mice. *Aging Cell, 24*(3), e14492. https://dx.doi.org/10.1111/acel.14492

Patysheva, M. R., Prostakishina, E. A., Budnitskaya, A. A., Bragina, O. D., & Kzhyshkowska, J. G. (2023). Dual-specificity phosphatases in regulation of tumor-associated macrophage activity. *International Journal of Molecular Sciences, 24*(24). https://dx.doi.org/10.3390/ijms242417542

Pramfalk, C., Eriksson, M., & Parini, P. (2015). Role of TG-interacting factor (Tgif) in lipid metabolism. *Biochimica et Biophysica Acta, 1851*(1), 9-12. https://dx.doi.org/10.1016/j.bbalip.2014.07.019

Priam, P., Krasteva, V., Rousseau, P., Polsinelli, A., Cote, L., Desanlis, I., . . . Lessard, J. A. (2024). Smarcd1 subunit of SWI/SNF chromatin-remodeling complexes collaborates with E2a to promote murine lymphoid specification. *Developmental Cell, 59*(23), 3124–3140 e3128. https://dx.doi.org/10.1016/j.devcel.2024.08.007

Qi, J., Wu, G., He, M., Xu, Y., Yang, Z., Ding, L., . . . Zhang, Z. (2024). CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers. *Aging, 16*(2), 1879–1896. https://dx.doi.org/10.18632/aging.205465

Qi, Q., Menzaghi, C., Smith, S., Liang, L., de Rekeneire, N., Garcia, M. E., . . . Qi, L. (2012). Genome-wide association analysis identifies TYW3/CRYZ and DNST4 loci associated with circulating resistin levels. *Human Molecular Genetics, 21*(21), 4774–4780. https://dx.doi.org/10.1093/hmg/dds300

Qu, H., Gong, X., Liu, X., Zhang, R., Wang, Y., Huang, B., . . . Zheng, Y. (2021). Deficiency of mitochondrial glycerol 3-phosphate dehydrogenase exacerbates podocyte injury and the progression of diabetic kidney disease. *Diabetes, 70*(6), 1372–1387. https://dx.doi.org/10.2337/db20-1157

Qu, L., Tang, Y., Wu, J., Yun, X., Lo, H. H., Song, L., . . . Law, B. Y. K. (2024). FBXL16: A new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein. *Biomarker Research, 12*(1), 144. https://dx.doi.org/10.1186/s40364-024-00691-w

Rahman, R., Islam, T., Shahjaman, J., Quinn, M. W., Holsinger, D., & Moni, M. A. (2018). Common molecular biomarker signatures in blood and brain of Alzheimer's disease. *bioRxiv*, 1–19. https://dx.doi.org/https://doi.org/10.1101/482828

Rattanapan, Y., Duangchan, T., Sai-Ong, T., & Chareonsirisuthigul, T. (2025). MiR-4428 and miR-185-5p as key modulators of insulin sensitivity and glucose homeostasis: Insights into pathways and therapeutic potential in type 2 diabetes mellitus. *Biology (Basel), 14*(4). https://dx.doi.org/10.3390/biology14040424

Reading, C., Yan, J., Testa, M. A., Simonson, D. C., Javaid, H., Schmunk, L., . . . Palumbo, J. (2025). An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease. *Frontiers in Neuroscience, 19*, 1516746. https://dx.doi.org/10.3389/fnins.2025.1516746

Reading, C. L., Flores-Riveros, J., Stickney, D. R., & Frincke, J. M. (2013). An anti-inflammatory sterol decreases obesity-related inflammation-induced insulin resistance and metabolic dysregulation. *Mediators of Inflammation, 2013*, 814989. https://dx.doi.org/10.1155/2013/814989

Reading, C. L., Stickney, D. R., Flores-Riveros, J., Destiche, D. A., Ahlem, C. N., Cefalu, W. T., & Frincke, J. M. (2013). A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects. *Obesity (Silver Spring), 21*(9), E343–349. https://dx.doi.org/10.1002/oby.20207

Reading, C., Yan, J., Schmunk, L., Martin-Herranz, D., Ahlem, C., Markham, P., O'Quinn, S., & Palumbo, J. (2025). Bezisterim epigenetic effects on aging and neurodegeneration. *Presented at: 7th World Aging and Rejuvenation Conference; July 9-10, 2025; Vienna, Austria*.

Ren, J., Chen, X., & Chen, Z. J. (2014). IKKβ is an IRF5 kinase that instigates inflammation. *Proceedings of the National Academy of Sciences of the United States of America, 111*(49), 17438–17443. https://dx.doi.org/10.1073/pnas.1418516111

Rorbach-Dolata, A., & Piwowar, A. (2019). Neurometabolic evidence supporting the hypothesis of increased incidence of type 3 diabetes mellitus in the 21st century. *BioMed Research International, 2019*, 1435276. https://dx.doi.org/10.1155/2019/1435276

Saddala, M. S., Yang, X., Tang, S., & Huang, H. (2021). Transcriptome-wide analysis reveals core sets of transcriptional regulators of sensome and inflammation genes in retinal microglia. *Genomics, 113*(5), 3058–3071. https://dx.doi.org/10.1016/j.ygeno.2021.07.001

Sanchez-Mut, J. V., Aso, E., Heyn, H., Matsuda, T., Bock, C., Ferrer, I., & Esteller, M. (2014). Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. *Hippocampus, 24*(4), 363–368. https://dx.doi.org/10.1002/hipo.22245

Sanchez-Mut, J. V., & Graff, J. (2015). Epigenetic alterations in Alzheimer's disease. *Frontiers in Behavioral Neuroscience, 9*, 347. https://dx.doi.org/10.3389/fnbeh.2015.00347

Sato, A., Nagai, M., Tagami, A., Natori, Y., & Okada, M. (1991). Effect of pyridoxine-deficiency on degradation of cytosolic aspartate aminotransferase in rat liver lysosomes. *Journal of*

Nutritional Science and Vitaminology, 37(4), 419–424.
https://dx.doi.org/10.3177/jnsv.37.419

Sehgal, R., Markov, Y., Qin, C., Meer, M., Hadley, C., Shadyab, A. H., . . . Levine, M. (2025). Systems age: A single blood methylation test to quantify aging heterogeneity across 11 physiological systems. *Nature Aging, 5*(9), 1880–1896. https://dx.doi.org/10.1038/s43587-025-00958-3

Sha, Y. L., Liu, Y., Yang, J. X., Wang, Y. Y., Gong, B. C., Jin, Y., . . . Zhao, Q. (2022). B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma. *Journal of Experimental and Clinical Cancer Research, 41*(1), 314. https://dx.doi.org/10.1186/s13046-022-02523-x

Sharma, V., Chander Sharma, P., Reang, J., Yadav, V., Kumar Tonk, R., Majeed, J., & Sharma, K. (2024). Impact of GSK-3β and CK-1δ on Wnt signaling pathway in Alzheimer disease: A dual target approach. *Bioorganic Chemistry, 147*, 107378. https://dx.doi.org/10.1016/j.bioorg.2024.107378

Shaughness, M., Acs, D., Brabazon, F., Hockenbury, N., & Byrnes, K. R. (2020). Role of insulin in neurotrauma and neurodegeneration: A review. *Frontiers in Neuroscience, 14*, 547175. https://dx.doi.org/10.3389/fnins.2020.547175

Skeete, J., & DiPette, D. J. (2017). Relationship between homocysteine and hypertension: New data add to the debate. *Journal of Clinical Hypertension, 19*(11), 1171–1172. https://dx.doi.org/10.1111/jch.13073

Song, R., Gao, Y., Dozmorov, I., Malladi, V., Saha, I., McDaniel, M. M., . . . Pasare, C. (2021). IRF1 governs the differential interferon-stimulated gene responses in human monocytes and macrophages by regulating chromatin accessibility. *Cell Reports, 34*(12), 108891. https://dx.doi.org/10.1016/j.celrep.2021.108891

Sorosina, M., Peroni, S., Mascia, E., Santoro, S., Osiceanu, A. M., Ferre, L., . . . Esposito, F. (2022). Involvement of NINJ2 protein in inflammation and blood-brain barrier transmigration of monocytes in multiple sclerosis. *Genes (Basel), 13*(11). https://dx.doi.org/10.3390/genes13111946

Srinivasan, K., Friedman, B. A., Etxeberria, A., Huntley, M. A., van der Brug, M. P., Foreman, O., . . . Hansen, D. V. (2020). Alzheimer's patient microglia exhibit enhanced aging and unique transcriptional activation. *Cell Reports, 31*(13), 107843. https://dx.doi.org/10.1016/j.celrep.2020.107843

Sugimoto-Ishige, A., Jodo, A., & Tanaka, T. (2025). Fbxo16 mediates degradation of NF-κB p65 subunit and inhibits inflammatory response in dendritic cells. *Frontiers in Immunology, 16*, 1524110. https://dx.doi.org/10.3389/fimmu.2025.1524110

Sun, L., Marin de Evsikova, C., Bian, K., Achille, A., Telles, E., Pei, H., & Seto, E. (2018). Programming and regulation of metabolic homeostasis by HDAC11. *eBioMedicine, 33*, 157–168. https://dx.doi.org/10.1016/j.ebiom.2018.06.025

Sun, S., Han, Y., Zhang, C., Liu, H., Wang, B., Cao, S., . . . Chen, Y. (2022). Adenosine kinase inhibition prevents severe acute pancreatitis via suppressing inflammation and acinar cell necroptosis. *Frontiers in Cell Developmental Biology, 10*, 827714. https://dx.doi.org/10.3389/fcell.2022.827714

Tan, S., Wang, Z., Li, N., Guo, X., Zhang, Y., Ma, H., . . . Ma, C. (2023). Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response. *Cell Death and Differentiation, 30*(9), 2104–2119. https://dx.doi.org/10.1038/s41418-023-01202-4

Tang, Q., Cai, J., Shen, D., Bian, Z., Yan, L., Wang, Y. X., . . . Wang, W. (2009). Lysosomal cysteine peptidase cathepsin l protects against cardiac hypertrophy through blocking AKT/GSK3β signaling. *Journal of Molecular Medicine (Berlin, Germany), 87*(3), 249–260. https://dx.doi.org/10.1007/s00109-008-0423-2

TGIF1. (2025). Tgfb induced factor homeobox 1. Retrieved from https://www.ncbi.nlm.nih.gov/gene/7050

Tikhanovich, I., Kuravi, S., Artigues, A., Villar, M. T., Dorko, K., Nawabi, A., . . . Weinman, S. A. (2015). Dynamic arginine methylation of tumor necrosis factor (TNF) receptor-associated factor 6 regulates toll-like receptor signaling. *Journal of Biological Chemistry, 290*(36), 22236–22249. https://dx.doi.org/10.1074/jbc.M115.653543

Tomusiak, A., Floro, A., Tiwari, R., Riley, R., Matsui, H., Andrews, N., . . . Verdin, E. (2024). Development of an epigenetic clock resistant to changes in immune cell composition. *Communications Biology, 7*(1), 934. https://dx.doi.org/10.1038/s42003-024-06609-4

Tong, H., Dwaraka, V. B., Chen, Q., Luo, Q., Lasky-Su, J. A., Smith, R., & Teschendorff, A. E. (2024). Quantifying the stochastic component of epigenetic aging. *Nature Aging, 4*(6), 886–901. https://dx.doi.org/10.1038/s43587-024-00600-8

Tsai, M. H., & Lee, C. K. (2018). STAT3 cooperates with phospholipid scramblase 2 to suppress type I interferon response. *Frontiers in Immunology, 9*, 1886. https://dx.doi.org/10.3389/fimmu.2018.01886

Unoki, M., Masuda, A., Dohmae, N., Arita, K., Yoshimatsu, M., Iwai, Y., . . . Nakamura, Y. (2013). Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6). *Journal of Biological Chemistry, 288*(9), 6053–6062. https://dx.doi.org/10.1074/jbc.M112.433284

van Dongen, J., Nivard, M. G., Baselmans, B. M., Zilhao, N. R., Ligthart, L., Consortium, B., . . . Boomsma, D. I. (2015). Epigenome-wide association study of aggressive behavior. *Twin Research Human Genetics, 18*(6), 686–698. https://dx.doi.org/10.1017/thg.2015.74

Vervoorts, J., Neumann, D., & Luscher, B. (2020). The CCNY (cyclin Y)-CDK16 kinase complex: A new regulator of autophagy downstream of AMPK. *Autophagy, 16*(9), 1724–1726. https://dx.doi.org/10.1080/15548627.2020.1795423

Wang, C., Zhang, P., Li, Y., Wang, X., Guo, L., Li, J., & Jiao, H. (2023). Downregulation of TRIM27 alleviates hypoxic-ischemic encephalopathy through inhibiting inflammation and microglia cell activation by regulating STAT3/HMGB1 axis. *Journal of Chemical Neuroanatomy, 129*, 102251. https://dx.doi.org/10.1016/j.jchemneu.2023.102251

Wang, N., Liang, H., & Zen, K. (2014). Molecular mechanisms that influence the macrophage M1-M2 polarization balance. *Frontiers in Immunology, 5*, 614. https://dx.doi.org/10.3389/fimmu.2014.00614

Wang, T., Villegas, S., Huang, Y., White, S. K., Ahlem, C., Lu, M., . . . Flores-Riveros, J. (2010). Amelioration of glucose intolerance by the synthetic androstene HE3286: Link to inflammatory pathways. *Journal of Pharmacology and Experimental Therapeutics, 333*(1), 70–80. https://dx.doi.org/10.1124/jpet.109.161182

Wang, X., Shi, N., Hui, M., Jin, H., Gao, S., Zhou, Q., . . . Shen, H. (2021). The impact of β-1,4-galactosyltransferase V on microglial function. *Frontiers in Cellular Neuroscience, 15*, 723308. https://dx.doi.org/10.3389/fncel.2021.723308

Wang, X., Yuan, X., Su, Y., Hu, J., Ji, Q., Fu, S., . . . Dai, C. (2021). Targeting purinergic receptor P2RX1 modulates intestinal microbiota and alleviates inflammation in colitis. *Frontiers in Immunology, 12*, 696766. https://dx.doi.org/10.3389/fimmu.2021.696766

Wang, Y., Wan, R., & Hu, C. (2023). Leptin/obR signaling exacerbates obesity-related neutrophilic airway inflammation through inflammatory M1 macrophages. *Molecular Medicine, 29*(1), 100. https://dx.doi.org/10.1186/s10020-023-00702-w

Wang, Z., Kong, L., Tan, S., Zhang, Y., Song, X., Wang, T., . . . Ma, C. (2020). Zhx2 accelerates sepsis by promoting macrophage glycolysis via Pfkfb3. *Journal of Immunology, 204*(8), 2232–2241. https://dx.doi.org/10.4049/jimmunol.1901246

Ward, A. J., Rimer, M., Killian, J. M., Dowling, J. J., & Cooper, T. A. (2010). CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. *Human Molecular Genetics, 19*(18), 3614–3622. https://dx.doi.org/10.1093/hmg/ddq277

Wei, L., Tian, Y., Chen, Y., Wei, Q., Chen, F., Cao, B., . . . Wang, K. (2019). Identification of TYW3/CRYZ and FGD4 as susceptibility genes for amyotrophic lateral sclerosis. *Neurology Genetics, 5*(6), e375. https://dx.doi.org/10.1212/NXG.0000000000000375

Wei, Y., & Li, X. (2022). Different phenotypes of microglia in animal models of Alzheimer disease. *Immunity & Ageing, 19*(1), 44. https://dx.doi.org/10.1186/s12979-022-00300-0

Wu, S., Mao, C., Kondiparthi, L., Poyurovsky, M. V., Olszewski, K., & Gan, B. (2022). A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria. *Proceedings of the National Academy of Sciences of the United States of America, 119*(26), e2121987119. https://dx.doi.org/10.1073/pnas.2121987119

Wunderlich, F. T., Luedde, T., Singer, S., Schmidt-Supprian, M., Baumgartl, J., Schirmacher, P., . . . Bruning, J. C. (2008). Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. *Proceedings of the National Academy of Sciences of the United States of America, 105*(4), 1297–1302. https://dx.doi.org/10.1073/pnas.0707849104

Xu, P., Ianes, C., Gartner, F., Liu, C., Burster, T., Bakulev, V., . . . Bischof, J. (2019). Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D). *Gene, 715*, 144005. https://dx.doi.org/10.1016/j.gene.2019.144005

Xu, S., Zhang, H., Yang, X., Qian, Y., & Xiao, Q. (2018). Inhibition of cathepsin l alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF-κB pathways. *Neurobiology of Aging, 62*, 159–167. https://dx.doi.org/10.1016/j.neurobiolaging.2017.09.030

Xu, Y., Tan, M., Tian, X., Zhang, J., Zhang, J., Chen, J., . . . Sheng, H. (2020). Leptin receptor mediates the proliferation and glucose metabolism of pancreatic cancer cells via AKT pathway activation. *Molecular Medicine Reports, 21*(2), 945–952. https://dx.doi.org/10.3892/mmr.2019.10855

Xu, Y., Wang, Y., Yan, S., Yang, Q., Zhou, Y., Zeng, X., . . . Huo, Y. (2017). Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. *Nature Communications, 8*(1), 943. https://dx.doi.org/10.1038/s41467-017-00986-7

Yan, S., Kumari, M., Xiao, H., Jacobs, C., Kochumon, S., Jedrychowski, M., . . . Rosen, E. D. (2021). IRF3 reduces adipose thermogenesis via ISG15-mediated reprogramming of glycolysis. *Journal of Clinical Investigation, 131*(7). https://dx.doi.org/10.1172/JCI144888

Yanagisawa, K. (2015). GM1 ganglioside and Alzheimer's disease. *Glycoconjugate Journal, 32*(3–4), 87–91. https://dx.doi.org/10.1007/s10719-015-9579-5

Yee, B. K., Singer, P., Chen, J. F., Feldon, J., & Boison, D. (2007). Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. *European Journal of Neuroscience, 26*(11), 3237–3252. https://dx.doi.org/10.1111/j.1460-9568.2007.05897.x

Yien, Y. Y., Robledo, R. F., Schultz, I. J., Takahashi-Makise, N., Gwynn, B., Bauer, D. E., . . . Paw, B. H. (2014). TMEM14C is required for erythroid mitochondrial heme metabolism. *Journal of Clinical Investigation, 124*(10), 4294–4304. https://dx.doi.org/10.1172/JCI76979

Ying, K., Liu, H., Tarkhov, A. E., Sadler, M. C., Lu, A. T., Moqri, M., . . . Gladyshev, V. N. (2024). Causality-enriched epigenetic age uncouples damage and adaptation. *Nature Aging, 4*(2), 231–246. https://dx.doi.org/10.1038/s43587-023-00557-0

You, J. E., Kim, E. J., Kim, H. W., Kim, J. S., Kim, K., & Kim, P. H. (2024). Exploring the role of guanylate-binding protein-2 in activated microglia-mediated neuroinflammation and neuronal damage. *Biomedicines, 12*(5). https://dx.doi.org/10.3390/biomedicines12051130

Yu, X., Rehman, A. U., Dang, L., Zhang, X., Liu, J., Xiong, X., . . . Jian, Z. (2025). Interferon regulatory factor 5: A potential target for therapeutic intervention in inflammatory diseases. *Frontiers in Immunology, 16*, 1535823. https://dx.doi.org/10.3389/fimmu.2025.1535823

Zarrella, J. A., & Tsurumi, A. (2024). Genome-wide transcriptome profiling and development of age prediction models in the human brain. *Aging, 16*(5), 4075–4094. https://dx.doi.org/10.18632/aging.205609

Zhang, H., Qin, X., Yuan, H., Xiang, L., & Yu, H. (2025). Cathepsin l aggravates neuroinflammation via promoting microglia M1 polarization and NLRP3 activation after spinal cord injury. *FASEB Journal, 39*(9), e70561. https://dx.doi.org/10.1096/fj.202403101R

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024). Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. *Signal Transduction Targeted Therapy, 9*(1), 211. https://dx.doi.org/10.1038/s41392-024-01911-3

Zhang, L., Silva, T. C., Young, J. I., Gomez, L., Schmidt, M. A., Hamilton-Nelson, K. L., . . . Wang, L. (2020). Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. *Nature Communications, 11*(1), 6114. https://dx.doi.org/10.1038/s41467-020-19791-w

Zhang, Q., Xia, Y., Wang, Y., Shentu, Y., Zeng, K., Mahaman, Y. A. R., . . . Wang, X. (2018). CK2 phosphorylating I(2)(PP2A)/SET mediates tau pathology and cognitive impairment. *Frontiers in Molecular Neuroscience, 11*, 146. https://dx.doi.org/10.3389/fnmol.2018.00146

Zhang, Y. X., Yang, L. P., Gai, C., Cheng, C. C., Guo, Z. Y., Sun, H. M., & Hu, D. (2022). Association between variants of MTHFR genes and psychiatric disorders: A meta-analysis. *Frontiers in Psychiatry, 13*, 976428. https://dx.doi.org/10.3389/fpsyt.2022.976428

Zhao, S., Chen, F., Hu, L., Li, X., Gao, Z., Chen, M., . . . Song, Z. (2025). Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy. *Frontiers in Immunology, 16*, 1523190. https://dx.doi.org/10.3389/fimmu.2025.1523190

Zhong, Q., Jiang, K., Zhang, F., Tian, Y., Gu, J., Li, T., . . . Sun, F. (2023). Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer. *American Journal of Cancer Research, 13*(6), 2213–2233. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/37424829

Zhou, J., Simon, J. M., Liao, C., Zhang, C., Hu, L., Zurlo, G., . . . Zhang, Q. (2022). An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. *Molecular Cell, 82*(16), 3030–3044 e3038. https://dx.doi.org/10.1016/j.molcel.2022.06.003

Zhou, Y., & Wu, Q. (2023). Spotlight on HOX cluster☐embedded antisense lncRNAs in cardiovascular diseases (review). *International Journal of Molecular Medicine, 52*(6). https://dx.doi.org/10.3892/ijmm.2023.5317

Zhou, Z., Zhong, L., Chu, X., Wan, P., Dan, W., Shao, X., . . . Liu, B. (2023). HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285. *Medical Oncology, 40*(11), 325. https://dx.doi.org/10.1007/s12032-023-02196-2

Tables

Table 1. Genes with potentially beneficial changes with DPM genes identified in Figure 2.

Increased DPM Genes	Promoter CpGs	DPM	*P* FDR < 0.05	Activity
HOXA4	15	+13%	1.6e-6	TF, epigenetic neuropathology, cognitive decline, inflammation, and atherosclerosis (Q. S. Li et al., 2021; Pai & Sukumar, 2020; Y. Zhou & Wu, 2023)
TYW3	15	+31%	2.6e-6	IR; aberrant ubiquitination in ALS, AD (Akrioti et al., 2022; Q. Qi et al., 2012; L. Wei et al., 2019)
B3GALT4	50	+6%	2.7e-5	Hypomethylated in AD brain, microglial neuroinflammation, pro-inflammatory kinase cascades, lipid dysregulation, neurodegeneration, and cognition (B3GALT4, 2025; Hayashi et al., 2004; Matsubara et al., 2017; Oikawa et al., 2015; Sha et al., 2022; X. Wang, Shi, et al., 2021; Yanagisawa, 2015)
CRYZ	13	+31%	1.8e-4	IR, aberrant ubiquitination in ALS, and AD (Akrioti et al., 2022; Y. Wei & Li, 2022)
CHPF	16	+11%	0.0007	Prion disease, inflammation, cognition, glycolysis, and obesity (Avram, Shaposhnikov, Buiu, & Mernea, 2014; Huynh et al., 2019; Liao et al., 2021; Meen et al., 2023; Zhong et al., 2023)
IKBKG	20	+6%	0.0011	Microglial neuroinflammation, kinase cascades, cognitive decline, neuron loss, glycolysis, M1 polarization, T2D, and obesity (Alanazi et al., 2025; Kracht, Muller-Ladner, & Schmitz, 2020; Londhe et al., 2018; Maqbool, Lattke, Wirth, & Baumann, 2013; N. Wang et al., 2014; Wunderlich et al., 2008)
TGIF1	23	+7%	0.0014	TF, inflammation, endothelial cytokines, dysregulated phosphoprotein, lipid, cholesterol, and chromatin remodeling (Chang et al., 2024; Friend, 2023; He et al., 2021; Hneino et al., 2012; Pramfalk, Eriksson, & Parini, 2015; *TGIF1*, 2025)
TRIM27	31	+11%	0.0014	Brain aging, obesity, cognitive decline, microglial neuroinflammation, significantly increased concentration in AD plasma (Ali et al., 2025; Kang, 2022; P. Li et al., 2025; C. Wang et al., 2023)
HDAC11	20	+9%	0.0015	Microglial neuroinflammation, Aβ, cognitive decline, lipid dysregulation, T2D, obesity, MAPK cascades, dysregulated phosphoprotein, cholesterol, obesity, and glycolysis (Bahl & Seto, 2021; Bai et al., 2025; Bi et al., 2021; Cao et al., 2019; H. Chen, Xie, Chen, & Zhuang, 2022; Nunez-Alvarez & Suelves, 2022; L. Sun et al., 2018; S. Sun et al., 2022; Z. Zhou et al., 2023)
ZHX2	7	+8%	0.001	TF, atherosclerosis, apoptosis, lipid, macrophage inflammation, M1 polarization, increased in AD plasma (Ali et al., 2025; Erbilgin et al., 2018; Tan et al., 2023; Z. Wang et al., 2020)
CUTA	49	+5%	0.0016	Cognitive decline, Aβ processing, increased in AD plasma (Ali et al., 2025; Hou et al., 2015)

Increased DPM Genes	Promoter CpGs	DPM	P FDR < 0.05	Activity
DGKZ	15	+6%	0.0017	Cognitive decline, kinase cascades, T2D, obesity, lipid, and cholesterol dysregulation (Begin, 2016; Benziane et al., 2017; Merida, Arranz-Nicolas, Rodriguez-Rodriguez, & Avila-Flores, 2019)
FYN	15	+11%	0.0021	Kinase cascades, neurotoxicity and synaptic impairments caused by Aβ, tau tyrosine phosphorylation, cognitive decline, microglial neuroinflammation, inflammasome, IR, and T2D (Bastie et al., 2007; Guglietti, Sivasankar, Mustafa, Corrigan, & Collins-Praino, 2021; Lee et al., 2013; Meur & Karati, 2025; Panicker et al., 2019)
GPD2	14	+6%	0.0021	Microglial neuroinflammation, M1 polarization, T2D, glycolysis, and lipid ferroptosis (*GDP2*, 2024; Langston et al., 2019; J. Lu et al., 2020; Oh et al., 2023; Oh et al., 2024; H. Qu et al., 2021; Wu et al., 2022; You et al., 2024)
JMJD6	18	+6%	0.0024	Cognitive decline, driver of AD network, Abeta, pTau, inflammation, *TRAF6*, NFκB, obesity, lipid metabolism; increased in AD plasma; nominated aging and AD target, forms 5-OH-lysine on histones and inhibits methylation (J. Agora, n.d.; Ali et al., 2025; Y. J. Hu et al., 2015; Merchant et al., 2023; Tikhanovich et al., 2015; Unoki et al., 2013; J. Zhou et al., 2022)
CELF1	28	+6%	0.0028	Inflammation, muscle wasting, nominated aging, and AD target (C. Agora, n.d.; Ward, Rimer, Killian, Dowling, & Cooper, 2010)
IRF5	14	+8%	0.0028	TF, chromatin remodeling, microglial neuroinflammation, Aβ pathology, M1 polarization, glycolysis, obesity, T2D, kinase cascades, and dysregulated phosphoprotein (Dalmas et al., 2015; Fang et al., 2023; Krausgruber et al., 2011; Ren, Chen, & Chen, 2014; Yu et al., 2025)
ADK	25	+5%	0.0031	Kinase cascades, inflammation, lipid dysregulation, cognitive decline (Ahmad et al., 2014; H. Li et al., 2023; S. Sun et al., 2022; Y. Xu et al., 2017; Yee, Singer, Chen, Feldon, & Boison, 2007)
CSNK2B	31	7%	0.0033	Kinase cascades, pTau, cognitive decline, astroglial neuroinflammation, increased in AD and FTD plasma (Ali et al., 2025; Rorbach-Dolata & Piwowar, 2019; Q. Zhang et al., 2018)
Decreased DPM Genes	**Promoter CpGs**	**DPM**	**P FDR < 0.05**	**Activity**
CDK16	18	-13%	0.002	Autophagy, decreased inflammatory gene expression and immune infiltration, suppressed M1 polarization, reduced Tau aggregation, enhanced neuronal function and survival (Garwain, Yerramilli, Romero, & Scarlata, 2020; J. Qi et al., 2024; Vervoorts, Neumann, & Luscher, 2020; C. Wang et al., 2023)

Decreased DPM Genes	Promoter CpGs	DPM	*P* FDR < 0.05	Activity
DUSP22	8	-7%	0.004	Anti-inflammatory phosphatase, hypermethylated in AD, expression decreases inflammatory kinase cascades and dysregulated phosphoproteins, decreases pTau, DNAm correlates with Braak stages, cognitive decline, PTSD and schizophrenia, expression is negatively correlated with glucose, obesity, cholesterol, and M1 polarization (An et al., 2021; Boks et al., 2018; Ge et al., 2022; Howie, Rijal, & Ressler, 2019; Patysheva, Prostakishina, Budnitskaya, Bragina, & Kzhyshkowska, 2023; Sanchez-Mut et al., 2014; Sanchez-Mut & Graff, 2015)
UBE2C	16	-11%	0.007	Reduces inflammation primarily by blocking the activation of NF-κB, can mitigate age-related cognitive decline, decreases inflammatory NFκB-related kinase cascades, decreased in AD plasma (Ali et al., 2025; Chitra, Nalini, & Rajasekhar, 2012; Elliott, Zollner, & Boehncke, 2003; Parker, Davidson, Osmulski, Gaczynska, & Pickering, 2025)
PLSCR2	7	-6%	0.010	Suppresses inflammation and M1 polarization, suppresses COVID by downregulating ACE2 (Ali et al., 2025; Lundstrom et al., 2023; R. Ma et al., 2025; Tsai & Lee, 2018)
NME3	8	-18%	0.016	Required for cell survival, reduces ROS and inflammation, and is required ciliary function (C. W. Chen, Tsao, Zhang, & Chang, 2020; Hoff et al., 2018)
SP140	6	-7%	0.024	Epigenetic reader that represses lineage-inappropriate genes such as *HOX* to maintain macrophage identity, differentially expressed in microglial neuroinflammation, decreases inflammatory gene expression, decreased transcripts in AD microglia with dementia and Braak stage (Citron et al., 2015; Fraschilla & Jeffrey, 2020; Karaky et al., 2018; Kosoy et al., 2025; Saddala, Yang, Tang, & Huang, 2021)
SLC9B2	22	-7%	0.025	Increases aging insulin signaling; absence of this protein leads to enhanced aging and obesity-induced glucose intolerance; maintains intracellular pH to inhibit shifting macrophages toward a pro-inflammatory (M1) phenotype; polarization and glycolysis; decreased transcripts in AD plasma with Braak stage and with dementia (Anderegg, Gyimesi, Ho, Hediger, & Fuster, 2022; Deisl et al., 2016; Kosoy et al., 2025)
LINC01806	3	-17%	0.026	Downregulated in AD with cognitive impairments, blood biomarker for cognitive impairment, decreases miR-44428 to improve insulin sensitivity and glucose homeostasis (Pantaleo et al., 2022; Rahman, 2018; Rattanapan, Duangchan, Sai-Ong, & Chareonsirisuthigul, 2025)
PARD6G-AS1	5	-10%	0.027	Cognition; correlation between methylation and aggressive behavior (van Dongen et al., 2015)
SSBP4	4	-9%	0.038	Improved cognition; transcription decreased with brain aging and cognitive decline (Zarrella & Tsurumi, 2024)

Decreased DPM Genes	Promoter CpGs	DPM	*P* FDR < 0.05	Activity
MAMSTR	7	-9%	0.038	Highly significant hypermethylated region in AD associated with Braak stages, microglial neuroinflammation, and cognitive decline; anti-inflammatory transcriptional coactivator of *MEF2C* that restrains microglial inflammatory response and is lost in brain aging in an IFN-I-dependent manner (Deczkowska et al., 2017; L. Zhang et al., 2020)
MIR4458HG	5	-6%	0.038	Decreases M1 polarization; increased expression promotes M2 (Zhao et al., 2025)
ISOC2	6	-9%	0.041	Maintains mitochondrial integrity, decreases inflammation related to senescence, and inhibits INK4a (*ISOC2*, 2025; Sato, Nagai, Tagami, Natori, & Okada, 1991)
SLC28A2-AS1	6	-11%	0.043	Improves cognition–*SLC28A2* is upregulated in aging brain, and may contribute to AD neurodegeneration (Aykac & Sehirli, 2020; Neutzner, Kohler, Frank, Killer, & Neutzner, 2023)
FXBL16	3	-19%	0.047	Accelerates degradation of APP, decreases microglial and astrocyte neuroinflammation and cognitive impairments, increased IRS1 stabilization and insulin signaling, decreases M1 polarization and kinase cascades and glycolysis, nominated aging and AD target (F. Agora, n.d.; Kim et al., 2021; Morel & Long, 2024; L. Qu et al., 2024; Sugimoto-Ishige, Jodo, & Tanaka, 2025)

Potentially beneficial activities for genes with significantly increased or decreased DPM are identified and referenced, inclusive of the number of promoter CpGs identified, the DPM percentage, and the FDR-adjusted *P*-value > 0.05 for each gene.

Aß, amyloid β; AD, Alzheimer's Disease; ALS, Amyotrophic Lateral Sclerosis; APP, amyloid precursor protein; CpG, 5'-cytosine-phosphate-guanine-3'; DNAm, methylated DNA; DPM, differential promoter methylation; FDR, false discovery rate; FTD, frontotemporal dementia; IFN-I, interferon type 1; INK4a, INhibitors of CDK4 a; IR, insulin resistance; IRS1, insulin receptor substrate; MAPK, mitogen-activated protein kinase; PTSD, post-traumatic stress disorder; ROS, reactive oxygen species; T2D, type-II diabetes; TF, transcription factor

Table 2. Shared Potentially Beneficial DPM (PBDPM) genes.

	Genes	Inflammation	%	Shared
Clock				
PCHorvath2	9	9	100	56
PCHannum	1	1	100	5
PCGrimAge	3	2	67	13
DamAge	5	5	100	39
IntrinClock	7	6	86	42
StocZhang	5	5	100	34
StocHorvath1	9	7	78	45
StocPhenoAge	12	10	83	64
RetroClock1&2	6	6	100	34
Clock-unique gene total	45	39	87	249
Traits				
Inflammation	354	354	100	1459
Cognition	189	153	81	887
T2D	156	125	80	837
Obesity	148	120	81	802
M1 polarization	146	136	93	759
Kinase cascades	143	127	89	722
Lipids	120	99	83	672
Glycolysis	90	69	77	498
Phosphoproteins	76	58	76	378
Nominated targets	37	31	84	202
Chromatin remodeling	75	68	91	398
TFs	78	67	86	409
Trait-unique gene total	447	354	79	1614
Clock- and trait-unique gene total	447	354	79	1670
Transcription				
Clock gene TF	7	6	86	44*
Unique PBDPM TFs associated with PBDPM gene transcription	40	33	89	190
Unique PBDPM genes transcribed by PBDPM TFs	437**	350	80	1668
Control				
SOMAscan&OLINK	113	0	0	0

Number of PBDPM genes identified; number and percentage associated with inflammation; total number of shared genes for each clock or trait, including transcription factors; and information related to PBDPM transcription by PBDPM transcription factors.

*Forty-three of 45 age deceleration clock genes can be transcribed by three TFs: *RUNX2*, *STAT3,* and *TCF12*.

**Four hundred thirty-seven of 447 PBDPM genes can be transcribed by the 78 PBDPM TFs; the other 10 genes do not have significantly identified TFs.

PBDPM, potentially beneficial differential promoter methylation; T2D, type-II diabetes; TF, transcription factor

Figures

Principal component first- and second-generation EAA clocks

Intrinsic and damage EAA clocks

Stochastic EAA clocks

Retroviral integration EAA clocks

Systems age EAA clocks

Figure 1. Decelerated aging in first- and second-generation aging clocks after 30 weeks of treatment with bezisterim. (A-M) Boxplots showing the medians (solid lines) and ranges (whiskers) of EAA of DNA samples from patients with AD following 7 months of treatment with bezisterim (green, n=17) or placebo (orange, n=16), as predicted by established PC first- and second-generation clocks **(A-C)**, intrinsic and damage clocks **(D-E)**, stochastic clocks **(F-H)**, retroviral integration clocks **(I-J)**, and systems age clocks **(K-M)**. Positive and negative values surrounding the dashed reference lines indicate accelerated and decelerated aging, respectively. *P* values are by unpaired t-tests with Welch correction.

AD, Alzheimer's Disease; EAA, epigenetic age acceleration; PC, principal component.

Figure 2. Differences in DPM genes following 7 months of treatment with bezisterim or placebo. (A-B) Treatment-dependent differences in promoter methylation are shown for 2,154 DPM genes with statistically significant FDR-adjusted P values below the $P < 0.001$ threshold **(A)** and 442 PBDPM genes within an adjusted threshold of $P > 0.001$ and $P < 0.05$ **(B)**. Average between-group differences in promoter methylation were computed for each of 447 genes. Positive and negative values indicate relative between-group decreases and increases in gene expression, respectively.

DPM, differential promoter methylation; FDR, false discovery rate; PBDPM, potentially beneficial differential promoter methylation

Figure 3. PBDPM clock genes. Forty-five clock PBDPM genes shared between 9 EAA clocks, 12 reported aging and AD traits, and AD, PD, and FTD, reported AD microglial dementia and Braak pathology scores, and details for PBDPM transcription factors that are known to transcribe the PBDPM genes.

AD, Alzheimer's Disease; EAA, epigenetic age acceleration; FTD, frontotemporal dementia;
PBDPM, potentially beneficial differential promoter methylation; PD, Parkinson's Disease; T2D,
type-II diabetes; TF, transcription factor

Table columns (left to right): UCSC_RefGene_Name, PCHorvath2 EAA, PCHannum EAA, PCGrimAge EAA, DamAge EAA, IntrinClock EAA, Stoch Zhang EAA, Stoch Horvath EAA, Stoch PhenoAge EAA, RetroClock V1/2 EAA, Inflammation, Cognition, Type 2 Diabetes, Obesity, M1 polarization, Kinase Cascade, Lipids, Glycolysis, Phosphoprotein, Nominated, Chromatin Reg., Transcription, Shared, AD Proteomics, PD Proteomics, FTD Proteomics, Dementia Transcripts, Braak Transcripts, TF transcribing PBDPM genes, Transcribed by PBDPM TF, No significant TF association

UCSC_RefGene_Name	Shared
AAK1	5
ABCA2	5
ABHD14A	4
ABHD14B	1
ABR	7
ACACA	6
ACAP1	5
ACAT2	6
ACBD4	2
ACOT8	4
ACOT9	5
ACP5	4
ACP6	7
ACVR1B	5
ADIPOR1	1
ADIPOR2	2
ADK	4
AGAP3	4
AGGF1	3
AHCY	2
AHCYL1	4
ALDH4A1	3
ALG3	1
AMPD2	2
AMPD3	5
ANKRA2	3
ANP32E	2
ANXA11	1
ANXA6	6
APPL2	2
ARF6	3
ARHGAP25	3
ARRB2	7
ARRDC3	6
ASF1B	2
ATAD3A	4
ATE1-AS1	1
ATG16L2	1
ATIC	1
ATR	2
AUP1	1
AZI2	2
B3GALT4	3
BAZ2A	2
BCAT1	5
BCL3	7
BHLHE40	7
BMP8B	1
BRCC3	1
BRD2	8
BTK	6
C1RL	3
C2	4
C6orf120	2
CACNA1C	4
CACNB3	3
CAMK2D	8
CAP1	2
CAPN2	5
CARD11	4
CASP7	3
CASP8	2
CBR3	3
CBX3	3
CD37	2
CD46	4
CD79B	2
CDC25A	3
CDC42	5
CDK12	3
CDK16	3
CDK19	7
CDK2AP1	1
CELF1	2
CENPM	1
CEP55	1
CFL2	1
CHAC1	1
CHD1L	1
CHEK2	4
CHPF	4
CLIC5	2
CMPK2	2
CPEB3	3
CREB1	7
CREB3L2	3
CREBZF	5
CRY1	2
CRYZ	1
CSNK1A1	2
CSNK1D	6
CSNK1G3	3
CSNK2B	3
CSRP1	3
CTSC	4
CTSL	3

UCSC_RefGene_Name	PCHorvath2 EAA	PCHannum EAA	PCGrimAge EAA	DamAge EAA	IntrinClock EAA	Stoch Zhang EAA	Stoch Horvath EAA	Stoch PhenoAge EAA	RetroClock V1/2 EAA	Inflammation	Cognition	Type 2 Diabetes	Obesity	M1 polarization	Kinase Cascade	Lipids	Glycolysis	Phosphoprotein	Nominated	Chromatin Reg.	Transcription	Shared	AD Proteomics	PD Proteomics	FTD Proteomics	Dementia Transcripts	Break Transcripts	TF transcribing PBDPM genes	Transcribed by PBDPM TF	No significant TF association
CUTA																						1								
DAPK2																						3								
DBI																						2								
DBT																						4								
DCAF6																						1								
DDB2																						5								
DDX20																						3								
DDX41																						3								
DDX46																						3								
DDX5																						5								
DEDD2																						2								
DENND1B																						4								
DGAT1																						5								
DGKZ																						6								
DHX16																						2								
DIABLO																						1								
DLG4																						1								
DLX2																						4								
DPP4																						6								
DUSP2																						4								
DUSP22																						8								
E2F2																						6								
E2F7																						4								
E2F8																						4								
EARS2																						6								
ECHDC1																						3								
EFNA4																						6								
EGR1																						5								
EGR2																						6								
EHMT1																						3								
EHMT2																						6								
EIF1AD																						1								
EIF2AK3																						4								
EIF4E																						8								
EIF5A																						6								
ELF1																						4								
ELOVL1																						4								
EML2																						1								
ENO3																						4								
EPHA4																						4								
ERBB2																						8								
ETV1																						4								
EXPH5																						1								
FAM163A																						2								
FBXL16																						7								
FDPS																						4								
FGD6																						1								
FKBP1A																						4								
FLII																						2								
FLNA																						3								
FOSB																						8								
FOXJ2																						7								
FOXO4																						5								
FTO																						6								
FUT8																						2								
FYN																						7								
GAB2																						6								
GADD45B																						1								
GALNT6																						2								
GATA3																						8								
GCA																						6								
GLUD1																						1								
GNA12																						3								
GNA13																						5								
GOT2																						2								
GPAT3																						6								
GPCPD1																						2								
GPD2																						5								
GTF2I																						3								
GTF3C2																						3								
H1-10																						2								
H2BC21																						3								
H2BC5																						2								
H2BC9																														
H3-3B																						4								
HASPIN																						6								
HCFC1																						3								
HDAC11																						6								
HDAC4																						9								
HEBP2																						5								
HEMK1																														
HEPACAM2																						1								
HIRA																														
HK2																						6								
HMGB1																						9								
HMGB2																						6								
HMGN1																						6								
HNRNPA2B1																						6								
HNRNPK																						8								
HOXA4																						5								
HSPA1A																						6								
HSPA1B																						6								
HSPA2																						6								
HSPBAP1																						4								
HTRA2																						4								
IFIH1																						5								

Table columns (left to right): UCSC_RefGene_Name, PCHorvath2 EAA, PCHannum EAA, PCGrimAge EAA, DamAge EAA, IntrinClock EAA, Stoch Zhang EAA, Stoch Horvath EAA, Stoch PhenoAge EAA, RetroClock V1/2 EAA, Inflammation, Cognition, Type 2 Diabetes, Obesity, M1 polarization, Kinase Cascade, Lipids, Glycolysis, Phosphoprotein, Nominated, Chromatin Reg., Transcription, Shared, AD Proteomics, PD Proteomics, FTD Proteomics, Dementia Transcripts, Braak Transcripts, TF transcribing PBDPM genes, Transcribed by PBDPM TF, No significant TF association

UCSC_RefGene_Name	Shared
IGF2BP3	5
IKBKB	7
IKBKG	7
IKZF1	4
IL12RB1	3
IL15	3
IL6R	6
IMPDH2	1
IRF1	8
IRF3i	8
IRF5	9
IRF7	10
ISOC2	1
ITGAL	6
ITGB8	1
ITPKB	2
ITPKC	4
ITPR2	2
JAK2	5
JDP2	2
JMJD6	8
KARS1	1
KCNN4	5
KCTD1	3
KCTD12	1
KDM2B	7
KDM4C	3
KDM5C	4
KLF10	6
KLF7	5
LAPTM5	4
LEPR	5
LHPP	1
LIME1	1
LINC01126	2
LINC01806	2
LIPG	5
LPCAT4	2
LZTFL1	2
MAF1	3
MAGT1	2
MAML1	5
MAMSTR	3
MAN2A2	1
MAP2K1	6
MAP2K3	8
MAP2K6	7
MAP3K12	6
MAP4K1	4
MAP4K5	3
MARK2	6
MARK3	4
MAT2A	6
MATR3	1
MBNL1	6
MCM2	3
MECP2	4
MGAT1	4
MIA3	1
MICB	1
MIR4458HG	1
MKRN1	3
MLF1	1
MPC1	2
MPI	3
MTHFR	5
MTOR	8
MTTP	5
MUTYH	2
MYL12A	3
MYO1G	1
N4BP2L1	1
NAGK	2
NARF	2
NEAT1	10
NEU1	3
NFE2L2	7
NFKB2	6
NFKBIA	8
NFKBIZ	9
NFYC	3
NINJ2	3
NLRP1	5
NME3	2
NOTCH4	3
NR3C1	6
NR3C2	4
NRBP1	4
NUBP1	1
OCIAD1	3
OSBPL11	3
P2RX1	5
PAFAH1B3	5
PAK1	8
PARD6G-AS1	1
PBX3	5

Table (page 52): Gene associations matrix. Columns: UCSC_RefGene_Name, PCHorvath2 EAA, PCHannum EAA, PCGrimAge EAA, DamAge EAA, IntrinClock EAA, Stoch Zhang EAA, Stoch Horvath EAA, Stoch PhenoAge EAA, RetroClock V1/2 EAA, Inflammation, Cognition, Type 2 Diabetes, Obesity, M1 polarization, Kinase Cascade, Lipids, Glycolysis, Phosphoprotein, Nominated, Chromatin Reg., Transcription, Shared, AD Proteomics, PD Proteomics, FTD Proteomics, Dementia Transcripts, Break Transcripts, TF transcribing PBDPM genes, Transcribed by PBDPM TF, No significant TF association.

UCSC_RefGene_Name	Shared
PCK2	3
PDE7A	2
PDK3	5
PDZD8	1
PEG10	2
PEMT	2
PFKFB4	5
PFKP	7
PGD	1
PGM1	3
PGPEP1	1
PGRMC1	4
PHACTR1	4
PIK3R1	5
PIK3R3	5
PIK3R5	5
PIM3	4
PIP4K2B	4
PITX1	2
PKM	7
PKNOX1	6
PLAU	3
PLCG2	4
PLSCR2	2
PLXNC1	3
POLR2A	4
POU2F2	3
PPP1R13L	1
PPP3CB	4
PQBP1	2
PRDX5	2
PRKAB2	4
PRKCA	8
PRKCI	3
PRKD2	6
PRKRA	4
PRKRIP1	4
PSMA1	1
PSMB1	4
PSMB10	5
PSMB3	2
PSMB9	1
PSMC5	3
PTEN	4
PTGER2	6
PTK2B	9
PTPN6	6
QRICH1	4
RAC1	9
RAI14	2
RBBP4	3
RBM15	6
RBM23	2
RFX5	2
RGS2	2
RLIM	3
RNF144B	1
RNF31	2
RNF4	1
RNY3	1
RUNX2	5
SAT1	5
SAT2	2
SCO2	4
SELPLG	6
SERBP1	1
SERPINB6	1
SF3A2	2
SF3A3	2
SGK3	6
SH2B3	1
SH3BGRL2	1
SH3GLB2	3
SIRT2	5
SIVA1	4
SLC15A4	2
SLC1A5	2
SLC25A12	1
SLC25A43	1
SLC28A2-AS1	1
SLC9A7	1
SLC9B2	3
SLU7	3
SMAD1	6
SMAD3	12
SMARCC1	6
SMARCD2	2
SMC3	4
SNRPA	2
SOAT1	8
SOD2	2
SP140	4
SP2	4
SP3	5
SQSTM1	5
SSBP4	1

Figure 4. Shared genes for all 447 PBDPM genes. Shared genes as in Figure 3.

AD, Alzheimer's Disease; EAA, epigenetic age acceleration; FTD, frontotemporal dementia;

PBDPM, PD, Parkinson's Disease; T2D, type-II diabetes; TF, transcription factor

Examples of bezisterim potentially beneficial DMP gene correlations with clinical measures

Examples of placebo potential risk DMP gene correlations with clinical measures

Figure 5. Correlations between genes and clinical measures. (A-F) Examples of significant correlations between clinical measures and PBDPM genes among AD patients treated with bezisterim, but not placebo. Differences in the sum of bezisterim promoter methylation compared to placebo are complementary to previously reported directional improvements in neurological assessments. **(G-L)** Examples of significant correlations between clinical measures and potential risk DPM genes among AD patients treated with placebo, but not bezisterim. AD, Alzheimer's Disease, ADAS-Cog12, Alzheimer's Disease Assessment Scale–Cognitive Subscale 12; ADCOMS, Alzheimer's Disease Composite Score; ADCS-ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory; CDR-SB, Clinicla Dementia Rating – Sum of Boxes; CGIC, Clinical Global Impression of Change; DPM, differential promoter methylation; GFAP, glial fibrillary acidic protein; GST, glutathione S-transferase; PBDPM, potentially beneficial differential promoter methylation

Figure 6. Correlations between genes and SBP. Significant positive correlations between six genes and SBP among placebo-treated AD patients. Boxed regions indicate decreased methylation of these six genes was associated with lower SBP, (indicated as BPs in the figure and the supplementary files) among placebo-treated patients, but not bezisterim-treated patients, which might result in decreased brain perfusion.

AD, Alzheimer's Dementia; BP, blood pressure; SBP, systolic blood pressure

Supporting Information

Additional supporting information can be found in Supplementary Files 1-4:

- **Supplementary File 1**
    - Table S1. DPM gene investigations
    - Table S2a. Master table of DPM genes
    - Table S2b. Master figure of DPM genes

- **Supplementary File 2**
    - Table S3. PCHorvath2.EAA
    - Table S4. PCHannum.EAA
    - Table S5. PCGrimAge.EAA
    - Table S6. DamAge.EAA
    - Table S7. IntrinClock.EAA
    - Table S8. StocZhang.EAA
    - Table S9. StocHorvath.EAA
    - Table S10. StocPhenoAge.EAA
    - Table S11. RetroClockV1&2
    - Table S12. Inflammation
    - Table S13. Cognition
    - Table S14. T2D
    - Table S15. Obesity
    - Table S16. M1 polarization
    - Table S17. Kinase cascades
    - Table S18. Lipids
    - Table S19. Glycolysis
    - Table S20. Phosphoproteins
    - Table S21. Nominated targets
    - Table S22. Chromatin remodeling
    - Table S23. Transcription factors
    - Table S24. AD proteomics
    - Table S25. PD proteomics
    - Table S26. FTD proteomics

- Table S27. Dementia transcripts
- Table S28. Braak transcripts
- Table S29. Transcription factors
- Table S30. ChEA_2022_
- Table S31. ENCODE
- Table S32. ChEA clock
- Table S33. ENCODE clock

- **Supplementary File 3. Links and additional information**

- **Supplementary File 4. Clinical gene correlations**
  - Table S34. Description of clinical measures used for correlations
  - Table S35. Bezisterim FDR < 0.05 significant correlations
  - Table S36. Placebo FDR < 0.05 significant correlations
  - Table S37. Bezisterim FDR < 0.05 multiple genes for same clinical measure
  - Table S38. Placebo FDR < 0.05 multiple genes for same clinical measure
  - Table S39. Bezisterim FDR < 0.05 correlations Z-score P versus placebo correlations
  - Table S40. Placebo FDR < 0.05 correlations Z-score P versus bezisterim correlations
  - Table S41. Bezisterim FDR < 0.01 correlation gene sharing & clinical measures
  - Table S42. Placebo FDR < 0.01 correlation gene sharing & bezisterim measures